export const mapData = [
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "Gracell Biotechnologies",
        marketValue: "1200",
        from: "Astrazeneca",
        to: 1,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Vaccines",
        companyName: "Omniose",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 2,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Vaccines",
        companyName: "Icosavax, Inc.",
        marketValue: "1100",
        from: "Astrazeneca",
        to: 3,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "CinCor Pharma, Inc",
        marketValue: "1800",
        from: "Astrazeneca",
        to: 4,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Absci",
        marketValue: "247",
        from: "Astrazeneca",
        to: 5,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "Neogene Therapeutics",
        marketValue: "320",
        from: "Astrazeneca",
        to: 6,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technology (TALEN based)",
        companyName: "Cellectis",
        marketValue: "245",
        from: "Astrazeneca",
        to: 7,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Minimal residual disease (MRD) testing",
        companyName: "C2i Genomics",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 8,
        sector: "Biotechnology",
    },
    {
        partnership: "Partnership",
        modality: "AI-powered diagnostics",
        companyName: "Ibex Medical Analytics ",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 9,
        sector: "Biotechnology",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Hospital Bellvitge",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 10,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Verge Genomics",
        marketValue: "882",
        from: "Astrazeneca",
        to: 11,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "QuellTX",
        marketValue: "2085",
        from: "Astrazeneca",
        to: 12,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "LaNova Medicines",
        marketValue: "600",
        from: "Astrazeneca",
        to: 13,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Small molecule Therapy",
        companyName: "Ascentage Pharma",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 14,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: " Implantable medical device",
        companyName: "Sernova Corp",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 15,
        sector: "Biotechnology",
    },
    {
        partnership: "Partnership",
        modality: "Minimal residual disease (MRD) testing",
        companyName: "Personalis, Inc.",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 16,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Protein Degradation Therapy",
        companyName: "Cullgen Inc",
        marketValue: "35",
        from: "Astrazeneca",
        to: 17,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technology (Pin-point based)",
        companyName: "Revvity",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 18,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Eccogene ",
        marketValue: "1985",
        from: "Astrazeneca",
        to: 19,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Cholesgen ",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 20,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "AI-powered diagnostics",
        companyName: "Qure.ai",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 21,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Partnership",
        modality: "Neuroscience Therapy",
        companyName: "JCR Pharmaceuticals Co., Ltd.",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 22,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Partnership",
        modality: " Implantable medical device",
        companyName: "Biora Therapeutics, Inc",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 23,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "AbelZeta Pharma",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 24,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "TeneoTwo, Inc.",
        marketValue: "100",
        from: "Astrazeneca",
        to: 25,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Neurimmune",
        marketValue: "760",
        from: "Astrazeneca",
        to: 26,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Illumina Inc",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 27,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "RQ Biotechnology Ltd ",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 28,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Gene therapy",
        companyName: "LogicBio Therapeutics, Inc.",
        marketValue: "68",
        from: "Astrazeneca",
        to: 29,
        sector: "Biotechnology",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "docdok.health",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 30,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Rgenta Therapeutics Inc",
        marketValue: "52",
        from: "Astrazeneca",
        to: 31,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Huma ",
        marketValue: "33",
        from: "Astrazeneca",
        to: 32,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Target Medicals LLC",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 33,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Caelum Biosciences, Inc.",
        marketValue: "500",
        from: "Astrazeneca",
        to: 34,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Alexion Pharmaceuticals, Inc.",
        marketValue: "3900",
        from: "Astrazeneca",
        to: 35,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Ionis",
        marketValue: "3.585",
        from: "Astrazeneca",
        to: 36,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "RNA Therapeutics",
        companyName: "VaxEquity",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 37,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Accent Therapeutics",
        marketValue: "55",
        from: "Astrazeneca",
        to: 38,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Silence Therapeutics",
        marketValue: "470",
        from: "Astrazeneca",
        to: 39,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Minimal residual disease (MRD) testing",
        companyName: "ArcherDX",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 40,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Dogma Therapeutics",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 41,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Daiichi Sankyo Company, Limited",
        marketValue: "6000",
        from: "Astrazeneca",
        to: 42,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "BenevolentAI ",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 43,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Aptamer Group",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 44,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Partnership",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Cancer Research UK",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 45,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Innate Pharma SA",
        marketValue: "875",
        from: "Astrazeneca",
        to: 46,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "IGI Research",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 47,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Pelago Bioscience",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 48,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Yiviva ",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 49,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "AI in clinical trials",
        companyName: "Sarah Cannon Research Institute (SCRI)",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 50,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Cellular Biomedicine Group Inc.",
        marketValue: "120",
        from: "Astrazeneca",
        to: 51,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Allorion Therapeutics ",
        marketValue: "540",
        from: "Astrazeneca",
        to: 52,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Bispecific antibodies",
        companyName: "Compugen Ltd",
        marketValue: "210",
        from: "Astrazeneca",
        to: 53,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Bispecific antibodies",
        companyName: "Presage Biosciences",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 54,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Minimal residual disease (MRD) testing",
        companyName: "IMBdx Inc.",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 55,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Nanoform Finland",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 56,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "KYM Biosciences",
        marketValue: "1163",
        from: "Astrazeneca",
        to: 57,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Ready-To-Use (RTU) infusion oncology products",
        companyName: "Sun Pharmaceutical Industries Ltd.",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 58,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "ProBioGen",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 59,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Regio Biosciences ",
        marketValue: "NA",
        from: "Astrazeneca",
        to: 60,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Yumanity Therapeutics\n(Kineta)",
        marketValue: "500",
        from: "Merck & Co",
        to: 61,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Xeris Pharmaceuticals",
        marketValue: "50",
        from: "Merck & Co",
        to: 62,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Viralytics Limited",
        marketValue: "394",
        from: "Merck & Co",
        to: 63,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Vaccines",
        companyName: "VelosBio Inc.",
        marketValue: "2750",
        from: "Merck & Co",
        to: 64,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "VectorY Therapeutics",
        marketValue: "140",
        from: "Merck & Co",
        to: 65,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Unnatural Products",
        marketValue: "32",
        from: "Merck & Co",
        to: 66,
        sector: "Biotechnology",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "Triumvira Immunologics",
        marketValue: "NA",
        from: "Merck & Co",
        to: 67,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Cytokine-based therapeutics",
        companyName: "TILT Biotherapeutics",
        marketValue: "NA",
        from: "Merck & Co",
        to: 68,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cytokine-based therapeutics",
        companyName: "Tilos Therapeutics, Inc.",
        marketValue: "773",
        from: "Merck & Co",
        to: 69,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Vaccines",
        companyName: "Themis Bio Holdings LLC",
        marketValue: "NA",
        from: "Merck & Co",
        to: 70,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cytokine-based therapeutics",
        companyName: "Synthekine Inc.",
        marketValue: "525",
        from: "Merck & Co",
        to: 71,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Syapse",
        marketValue: "NA",
        from: "Merck & Co",
        to: 72,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Ridgeback Biotherapeutics LP",
        marketValue: "NA",
        from: "Merck & Co",
        to: 73,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Proxygen ",
        marketValue: "2550",
        from: "Merck & Co",
        to: 74,
        sector: "Biotechnology",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Prometheus Biosciences",
        marketValue: "10800",
        from: "Merck & Co",
        to: 75,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Pragma Bio",
        marketValue: "10",
        from: "Merck & Co",
        to: 76,
        sector: "Biotechnology",
    },
    {
        partnership: "Partnership",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Philogen S.p.A",
        marketValue: "NA",
        from: "Merck & Co",
        to: 77,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Phanes Therapeutics, Inc",
        marketValue: "NA",
        from: "Merck & Co",
        to: 78,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Peloton Therapeutics",
        marketValue: "1150",
        from: "Merck & Co",
        to: 79,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "PDS Biotechnology Corp.",
        marketValue: "NA",
        from: "Merck & Co",
        to: 80,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "Pandion Therapeutics, Inc.",
        marketValue: "1850",
        from: "Merck & Co",
        to: 81,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "AI-powered diagnostics",
        companyName: "Owkin",
        marketValue: "NA",
        from: "Merck & Co",
        to: 82,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Orna Therapeutics",
        marketValue: "153.6",
        from: "Merck & Co",
        to: 83,
        sector: "Biotechnology",
    },
    {
        partnership: "Partnership",
        modality: "Gene therapy",
        companyName: "OncoSec Medical",
        marketValue: "NA",
        from: "Merck & Co",
        to: 84,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "OncoImmune, Inc.",
        marketValue: "475",
        from: "Merck & Co",
        to: 85,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "NGM Biopharmaceuticals",
        marketValue: "120",
        from: "Merck & Co",
        to: 86,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Moderna Therapeutics ",
        marketValue: "125",
        from: "Merck & Co",
        to: 87,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Lava Therapeutics",
        marketValue: "NA",
        from: "Merck & Co",
        to: 88,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Kelun Biotech",
        marketValue: "9475",
        from: "Merck & Co",
        to: 89,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "IRBM",
        marketValue: "NA",
        from: "Merck & Co",
        to: 90,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Vaccines",
        companyName: "Instituto Butantan",
        marketValue: "NA",
        from: "Merck & Co",
        to: 91,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "Immune Design Corp.",
        marketValue: "300",
        from: "Merck & Co",
        to: 92,
        sector: "Biotechnology",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Imago BioSciences",
        marketValue: "1350",
        from: "Merck & Co",
        to: 93,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "ImaginAb",
        marketValue: "NA",
        from: "Merck & Co",
        to: 94,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Small molecule Therapy",
        companyName: "HiberCell, Inc.",
        marketValue: "NA",
        from: "Merck & Co",
        to: 95,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Harpoon Therapeutics",
        marketValue: "680",
        from: "Merck & Co",
        to: 96,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Hanmi Pharmaceutical",
        marketValue: "870",
        from: "Merck & Co",
        to: 97,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Gilead ",
        marketValue: "NA",
        from: "Merck & Co",
        to: 98,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Targeted Alpha Therapies (TATs)",
        companyName: "Fusion Pharmaceuticals",
        marketValue: "NA",
        from: "Merck & Co",
        to: 99,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Evaxion Biotech",
        marketValue: "5.29",
        from: "Merck & Co",
        to: 100,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Combination Therapy",
        companyName: "Eisai",
        marketValue: "5700",
        from: "Merck & Co",
        to: 101,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Daiichi Sankyo Company, Limited",
        marketValue: "5500",
        from: "Merck & Co",
        to: 102,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Clinithink",
        marketValue: "NA",
        from: "Merck & Co",
        to: 103,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "ClearDATA",
        marketValue: "26",
        from: "Merck & Co",
        to: 104,
        sector: "Biotechnology",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "Carisma Therapeutics",
        marketValue: "NA",
        from: "Merck & Co",
        to: 105,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "Caraway Therapeutics",
        marketValue: "610",
        from: "Merck & Co",
        to: 106,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Calporta Therapeutics, Inc.",
        marketValue: "576",
        from: "Merck & Co",
        to: 107,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "BJ Bioscience, Inc.",
        marketValue: "NA",
        from: "Merck & Co",
        to: 108,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Vaccines",
        companyName: "Bill & Melinda Gates Foundation",
        marketValue: "NA",
        from: "Merck & Co",
        to: 109,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Astex Pharmaceuticals ",
        marketValue: "535",
        from: "Merck & Co",
        to: 110,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "ArQule",
        marketValue: "2700",
        from: "Merck & Co",
        to: 111,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Aitia ",
        marketValue: "28",
        from: "Merck & Co",
        to: 112,
        sector: "Biotechnology",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Acceleron Pharma Inc.",
        marketValue: "11500",
        from: "Merck & Co",
        to: 113,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "A2 Bio",
        marketValue: "NA",
        from: "Merck & Co",
        to: 114,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: " C4 Therapeutics, Inc.",
        marketValue: "2600",
        from: "Merck & Co",
        to: 115,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "AI-powered diagnostics",
        companyName: "Perceiv AI ",
        marketValue: "NA",
        from: "Merck & Co",
        to: 116,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "AI in clinical trials",
        companyName: "M2GEN",
        marketValue: "NA",
        from: "Merck & Co",
        to: 117,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "AI in clinical trials",
        companyName: "GNS Healthcare",
        marketValue: "28",
        from: "Merck & Co",
        to: 118,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Microbiome-based therapies",
        companyName: "4D pharma",
        marketValue: "341",
        from: "Merck & Co",
        to: 119,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "AI-powered diagnostics",
        companyName: "PreciseDx",
        marketValue: "10.75",
        from: "Merck & Co",
        to: 120,
        sector: "Biotechnology",
    },
    {
        partnership: "Partnership",
        modality: "AI in clinical trials",
        companyName: "Saama Technologies",
        marketValue: "NA",
        from: "Merck & Co",
        to: 121,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "AI in clinical trials",
        companyName: "Turbine",
        marketValue: "20",
        from: "Merck & Co",
        to: 122,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "AI in clinical trials",
        companyName: "TriNetX",
        marketValue: "40",
        from: "Merck & Co",
        to: 123,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Non-invasive healthcare devices",
        companyName: "Tasso Inc",
        marketValue: "17",
        from: "Merck & Co",
        to: 124,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Navigating cancer",
        marketValue: "26",
        from: "Merck & Co",
        to: 125,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Infectious Disease connect",
        marketValue: "5",
        from: "Merck & Co",
        to: 126,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Vaccines",
        companyName: "ModeX Therapeutics",
        marketValue: "922.5",
        from: "Merck & Co",
        to: 127,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "AI in clinical trials",
        companyName: "Absci",
        marketValue: "NA",
        from: "Merck & Co",
        to: 128,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Simcere Zaiming",
        marketValue: "NA",
        from: "Merck & Co",
        to: 129,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Multiple modalities",
        companyName: "Allergan",
        marketValue: "63000",
        from: "AbbVie",
        to: 130,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Neuroscience Therapy",
        companyName: "Mitokinin",
        marketValue: "655",
        from: "AbbVie",
        to: 131,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "ImmunoGen",
        marketValue: "10100",
        from: "AbbVie",
        to: 132,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Tissue engineering",
        companyName: "BioMed X Institute",
        marketValue: "NA",
        from: "AbbVie",
        to: 133,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "Calico Life Sciences",
        marketValue: "1000",
        from: "AbbVie",
        to: 134,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Genomics analysis",
        companyName: "M42",
        marketValue: "NA",
        from: "AbbVie",
        to: 135,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Small molecule Therapy",
        companyName: "Jacobio Pharmaceuticals",
        marketValue: "NA",
        from: "AbbVie",
        to: 136,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Umoja Biopharma",
        marketValue: "1440",
        from: "AbbVie",
        to: 137,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "Caribou Biosciences",
        marketValue: "340",
        from: "AbbVie",
        to: 138,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Regenxbio",
        marketValue: "1750",
        from: "AbbVie",
        to: 139,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Capsida Biotherapeutics Inc.",
        marketValue: "665",
        from: "AbbVie",
        to: 140,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Voyager Therapeutics",
        marketValue: "224",
        from: "AbbVie",
        to: 141,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Atomwise",
        marketValue: "123",
        from: "AbbVie",
        to: 142,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "DJS Antibodies",
        marketValue: "255",
        from: "AbbVie",
        to: 143,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "Mavupharma",
        marketValue: "NA",
        from: "AbbVie",
        to: 144,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Small molecule Therapy",
        companyName: "Scripps Research",
        marketValue: "NA",
        from: "AbbVie",
        to: 145,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Protein Degradation Therapy",
        companyName: "Frontier Medicines",
        marketValue: "NA",
        from: "AbbVie",
        to: 146,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Leukemia & Lymphoma Society",
        marketValue: "NA",
        from: "AbbVie",
        to: 147,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "HotSpot Therapeutics",
        marketValue: "335",
        from: "AbbVie",
        to: 148,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "BigHat Biosciences",
        marketValue: "355",
        from: "AbbVie",
        to: 149,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "AI in clinical trials",
        companyName: "Caris Life Sciences and ConcertAI",
        marketValue: "NA",
        from: "AbbVie",
        to: 150,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein Degradation Therapy",
        companyName: "I-Mab",
        marketValue: "1940",
        from: "AbbVie",
        to: 151,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Cugene Inc.",
        marketValue: "48.5",
        from: "AbbVie",
        to: 152,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "AbCellera Biologics Inc.",
        marketValue: "NA",
        from: "AbbVie",
        to: 153,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Morphic Therapeutic",
        marketValue: "100",
        from: "AbbVie",
        to: 154,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Disco Pharmaceuticals",
        marketValue: "22",
        from: "AbbVie",
        to: 155,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Multiple modalities",
        companyName: "Calibr",
        marketValue: "NA",
        from: "AbbVie",
        to: 156,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Anima Biotech",
        marketValue: "582",
        from: "AbbVie",
        to: 157,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Therapeutic devices",
        companyName: "Lyndra Therapeutics",
        marketValue: "101",
        from: "AbbVie",
        to: 158,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Lupin",
        marketValue: "30",
        from: "AbbVie",
        to: 159,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Immunome",
        marketValue: "NA",
        from: "AbbVie",
        to: 160,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Caraway Therapeutics",
        marketValue: "267",
        from: "AbbVie",
        to: 161,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Neuroscience Therapy",
        companyName: "Cerevel Therapeutics",
        marketValue: "8700",
        from: "AbbVie",
        to: 162,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Therapeutic devices",
        companyName: "iSTAR Medical",
        marketValue: "535",
        from: "AbbVie",
        to: 163,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "Syndesi Therapeutics",
        marketValue: "1000",
        from: "AbbVie",
        to: 164,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Bispecific antibodies",
        companyName: "Teneobio Inc. ",
        marketValue: "90",
        from: "AbbVie",
        to: 165,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Kojin TX",
        marketValue: "60",
        from: "AbbVie",
        to: 166,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Tizona Therapeutics",
        marketValue: "NA",
        from: "AbbVie",
        to: 167,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Galapagos (cystic fibrosis pipeline)",
        marketValue: "45",
        from: "AbbVie",
        to: 168,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "ArgenX",
        marketValue: "625",
        from: "AbbVie",
        to: 169,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Accent Therapeutics",
        marketValue: "63",
        from: "AbbVie",
        to: 170,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein Degradation Therapy",
        companyName: "Ambagon Therapeutics",
        marketValue: "85",
        from: "AbbVie",
        to: 171,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Artios Pharma Limited",
        marketValue: "84",
        from: "AbbVie",
        to: 172,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Enthera Pharmaceuticals",
        marketValue: "38.5",
        from: "AbbVie",
        to: 173,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Jnana Therapeutics",
        marketValue: "50",
        from: "AbbVie",
        to: 174,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "Nitrase Therapeutics (previously Nitrome Biosciences)",
        marketValue: "38",
        from: "AbbVie",
        to: 175,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Glyco-immunology based therapeutics",
        companyName: "Palleon Pharmaceuticals",
        marketValue: "100",
        from: "AbbVie",
        to: 176,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Quanta Therapeutics",
        marketValue: "50",
        from: "AbbVie",
        to: 177,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Ribometrix",
        marketValue: "30",
        from: "AbbVie",
        to: 178,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Therapeutic devices",
        companyName: "Stemson Therapeutics",
        marketValue: "15",
        from: "AbbVie",
        to: 179,
        sector: "Biotechnology",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Trishula Therapeutics",
        marketValue: "NA",
        from: "AbbVie",
        to: 180,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Carisma Therapeutics",
        marketValue: "53",
        from: "AbbVie",
        to: 181,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Center for Biologics Technical Development",
        marketValue: "122",
        from: "Novartis",
        to: 182,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Chinook Therapeutics",
        marketValue: "3500",
        from: "Novartis",
        to: 183,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Xiidra",
        marketValue: "5300",
        from: "Novartis",
        to: 184,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Pfizer",
        marketValue: "NA",
        from: "Novartis",
        to: 185,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Dawn Health",
        marketValue: "NA",
        from: "Novartis",
        to: 186,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Partnership",
        modality: "RNA Therapeutics",
        companyName: "Alnylam Pharmaceuticals",
        marketValue: "NA",
        from: "Novartis",
        to: 187,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Drugs for Neglected Diseases initiative",
        marketValue: "NA",
        from: "Novartis",
        to: 188,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "CellforCure",
        marketValue: "NA",
        from: "Novartis",
        to: 189,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "University of Pennsylvania",
        marketValue: "NA",
        from: "Novartis",
        to: 190,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Gene therapy",
        companyName: "Gyroscope Therapeutics",
        marketValue: "1500",
        from: "Novartis",
        to: 191,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Gene therapy",
        companyName: "AveXis, Inc.",
        marketValue: "8700",
        from: "Novartis",
        to: 192,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Gene therapy",
        companyName: "Vedere Bio",
        marketValue: "280",
        from: "Novartis",
        to: 193,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Gene therapy",
        companyName: "Bill & Melinda Gates Foundation",
        marketValue: "NA",
        from: "Novartis",
        to: 194,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Voyager Therapeutics",
        marketValue: "1200",
        from: "Novartis",
        to: 195,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Gene therapy",
        companyName: "Sangamo Therapeutics",
        marketValue: "NA",
        from: "Novartis",
        to: 196,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "AI in clinical trials",
        companyName: "Yseop",
        marketValue: "NA",
        from: "Novartis",
        to: 197,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Isomorphic Labs",
        marketValue: "37.5",
        from: "Novartis",
        to: 198,
        sector: "Biotechnology",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "BioCurate Pty Ltd",
        marketValue: "NA",
        from: "Novartis",
        to: 199,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Koneksa",
        marketValue: "45",
        from: "Novartis",
        to: 200,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Acquisition",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Calypso Biotech BV",
        marketValue: "425",
        from: "Novartis",
        to: 201,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "AI in clinical trials",
        companyName: "University of Oxford",
        marketValue: "NA",
        from: "Novartis",
        to: 202,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "BeiGene",
        marketValue: "2895",
        from: "Novartis",
        to: 203,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Mesoblast Ltd.",
        marketValue: "50",
        from: "Novartis",
        to: 204,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "RNA Therapeutics",
        companyName: "DTx Pharm",
        marketValue: "500",
        from: "Novartis",
        to: 205,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Radiopharmaceutical therapy",
        companyName: "Bicycle Therapeutics",
        marketValue: "1750",
        from: "Novartis",
        to: 206,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "Fraunhofer IZI",
        marketValue: "NA",
        from: "Novartis",
        to: 207,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Investment",
        modality: "Therapeutic devices",
        companyName: "Credence MedSystems",
        marketValue: "NA",
        from: "Novartis",
        to: 208,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Acquisition",
        modality: "Therapeutic devices",
        companyName: "Kedalion Therapeutics",
        marketValue: "NA",
        from: "Novartis",
        to: 209,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "AbCellera Biologics Inc.",
        marketValue: "NA",
        from: "Novartis",
        to: 210,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "The Medicines Company",
        marketValue: "9700",
        from: "Novartis",
        to: 211,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Microsoft",
        marketValue: "NA",
        from: "Novartis",
        to: 212,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "UCB",
        marketValue: "1650",
        from: "Novartis",
        to: 213,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Octave Bioscience",
        marketValue: "30",
        from: "Novartis",
        to: 214,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "The University of Manchester",
        marketValue: "3.5",
        from: "Novartis",
        to: 215,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "Carisma Therapeutics",
        marketValue: "NA",
        from: "Novartis",
        to: 216,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "Precision BioSciences",
        marketValue: "1475",
        from: "Novartis",
        to: 217,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Elsevier",
        marketValue: "NA",
        from: "Novartis",
        to: 218,
        sector: "Biotechnology",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Becton, Dickinson and Company",
        marketValue: "NA",
        from: "Novartis",
        to: 219,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Celcuity",
        marketValue: "NA",
        from: "Novartis",
        to: 220,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "SanReno Therapeutics",
        marketValue: "NA",
        from: "Novartis",
        to: 221,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Avrobio",
        marketValue: "87.5",
        from: "Novartis",
        to: 222,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Flare Therapeutics",
        marketValue: "123",
        from: "Novartis",
        to: 223,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Deciphex",
        marketValue: "11.5",
        from: "Novartis",
        to: 224,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Holmusk",
        marketValue: "45",
        from: "Novartis",
        to: 225,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Orionis Biosciences",
        marketValue: "NA",
        from: "Novartis",
        to: 226,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Radiopharmaceutical therapy",
        companyName: "Aktis Oncology",
        marketValue: "72",
        from: "Novartis",
        to: 227,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "AI-powered diagnostics",
        companyName: "Cleerly",
        marketValue: "223",
        from: "Novartis",
        to: 228,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Therapeutics for Food allergy",
        companyName: "Alladapt Immunotherapeutics",
        marketValue: "119",
        from: "Novartis",
        to: 229,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Dunad Therapeutics",
        marketValue: "1324",
        from: "Novartis",
        to: 230,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Gene therapy",
        companyName: "Arctos Medical",
        marketValue: "NA",
        from: "Novartis",
        to: 231,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Genomics analysis",
        companyName: "SomaLogic",
        marketValue: "NA",
        from: "Novartis",
        to: 232,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Non-invasive healthcare devices",
        companyName: "Dopavision",
        marketValue: "13.2",
        from: "Novartis",
        to: 233,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Acquisition",
        modality: "Neuroscience Therapy",
        companyName: "Cadent Therapeutics",
        marketValue: "770",
        from: "Novartis",
        to: 234,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "TScan Therapeutics",
        marketValue: "30",
        from: "Novartis",
        to: 235,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Aspen RxHealth",
        marketValue: "23",
        from: "Novartis",
        to: 236,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Molecular Partners",
        marketValue: "241.5",
        from: "Novartis",
        to: 237,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Pliant Therapeutics",
        marketValue: "80",
        from: "Novartis",
        to: 238,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Digital health tool",
        companyName: "Amblyotech",
        marketValue: "NA",
        from: "Novartis",
        to: 239,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Forendo Pharma",
        marketValue: "NA",
        from: "Novartis",
        to: 240,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Therapeutic devices",
        companyName: "SiO2 Medical Products",
        marketValue: "NA",
        from: "Novartis",
        to: 241,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Iconic Therapeutics",
        marketValue: "NA",
        from: "Novartis",
        to: 242,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Xealth",
        marketValue: "11",
        from: "Novartis",
        to: 243,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Ayala Pharmaceuticals",
        marketValue: "10",
        from: "Novartis",
        to: 244,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "IFM Tre",
        marketValue: "1575",
        from: "Novartis",
        to: 245,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Anthos Therapeutics",
        marketValue: "NA",
        from: "Novartis",
        to: 246,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Radiopharmaceutical therapy",
        companyName: "Endocyte",
        marketValue: "2100",
        from: "Novartis",
        to: 247,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "RxLightning",
        marketValue: "17.5",
        from: "Novartis",
        to: 248,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Pear Therapeutics",
        marketValue: "NA",
        from: "Novartis",
        to: 249,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Enterprise Therapeutics",
        marketValue: "33.1",
        from: "Novartis",
        to: 250,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Therapeutics for Food allergy",
        companyName: "Aravax",
        marketValue: "42",
        from: "Novartis",
        to: 251,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Hyku Biosciences",
        marketValue: "56",
        from: "Novartis",
        to: 252,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "FORE Biotherapeutics",
        marketValue: "75",
        from: "Novartis",
        to: 253,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Tagworks Pharmaceuticals",
        marketValue: "65",
        from: "Novartis",
        to: 254,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Oculis",
        marketValue: "NA",
        from: "Novartis",
        to: 255,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Catalym",
        marketValue: "49",
        from: "Novartis",
        to: 256,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Capstan Therapeutics",
        marketValue: "165",
        from: "Novartis",
        to: 257,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "SpliceBio",
        marketValue: "55",
        from: "Novartis",
        to: 258,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Epsilogen",
        marketValue: "40.9",
        from: "Novartis",
        to: 259,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Akouos",
        marketValue: "50",
        from: "Novartis",
        to: 260,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Radiopharmaceutical therapy",
        companyName: "Artios",
        marketValue: "1300",
        from: "Novartis",
        to: 261,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Appetite-Suppression Medication",
        companyName: "EraCal Therapeutics",
        marketValue: "1.13",
        from: "Novartis",
        to: 262,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Exo Therapeutics",
        marketValue: "78",
        from: "Novartis",
        to: 263,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "GentiBio",
        marketValue: "157",
        from: "Novartis",
        to: 264,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "LoQus23 Therapeutics",
        marketValue: "12.65",
        from: "Novartis",
        to: 265,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Rappta Therapeutics",
        marketValue: "10",
        from: "Novartis",
        to: 266,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Renovacor",
        marketValue: "11",
        from: "Novartis",
        to: 267,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "VantAI",
        marketValue: "674",
        from: "Bristol-Myers Squibb",
        to: 268,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Mirati Therapeutics",
        marketValue: "5800",
        from: "Bristol-Myers Squibb",
        to: 269,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Neuroscience Therapy",
        companyName: "Karuna Therapeutics",
        marketValue: "14000",
        from: "Bristol-Myers Squibb",
        to: 270,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "MEDiC Life Sciences",
        marketValue: "NA",
        from: "Bristol-Myers Squibb",
        to: 271,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Karyopharm Therapeutics",
        marketValue: "NA",
        from: "Bristol-Myers Squibb",
        to: 272,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Radiopharmaceutical therapy",
        companyName: "Ratio Therapeutics",
        marketValue: "50",
        from: "Bristol-Myers Squibb",
        to: 273,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Avidity Biosciences",
        marketValue: "2300",
        from: "Bristol-Myers Squibb",
        to: 274,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Radiopharmaceutical therapy",
        companyName: "RayzeBio",
        marketValue: "4100",
        from: "Bristol-Myers Squibb",
        to: 275,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "EvolveImmune Therapeutics",
        marketValue: "37",
        from: "Bristol-Myers Squibb",
        to: 276,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Q32 Bio",
        marketValue: "42",
        from: "Bristol-Myers Squibb",
        to: 277,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "in vitro diagnostic (IVD) genome testing",
        companyName: "Precede Biosciences ",
        marketValue: "57",
        from: "Bristol-Myers Squibb",
        to: 278,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Small molecule Therapy",
        companyName: "Terray Therapeutics",
        marketValue: "NA",
        from: "Bristol-Myers Squibb",
        to: 279,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Bispecific antibodies",
        companyName: "Zenas BioPharma ",
        marketValue: "50",
        from: "Bristol-Myers Squibb",
        to: 280,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Orum Therapeutics",
        marketValue: "280",
        from: "Bristol-Myers Squibb",
        to: 281,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Tubulis",
        marketValue: "1022.75",
        from: "Bristol-Myers Squibb",
        to: 282,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Small molecule Therapy",
        companyName: "CHARM Therapeutics",
        marketValue: "NA",
        from: "Bristol-Myers Squibb",
        to: 283,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: " Automated drug manufacturing technology",
        companyName: "Cellares",
        marketValue: "255",
        from: "Bristol-Myers Squibb",
        to: 284,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Immatics",
        marketValue: "760",
        from: "Bristol-Myers Squibb",
        to: 285,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "GentiBio",
        marketValue: "1900",
        from: "Bristol-Myers Squibb",
        to: 286,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Volastra Therapeutics",
        marketValue: "1130",
        from: "Bristol-Myers Squibb",
        to: 287,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Envisagenics",
        marketValue: "NA",
        from: "Bristol-Myers Squibb",
        to: 288,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein Degradation Therapy",
        companyName: "SyntheX",
        marketValue: "550",
        from: "Bristol-Myers Squibb",
        to: 289,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Century Therapeutics",
        marketValue: "3150",
        from: "Bristol-Myers Squibb",
        to: 290,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "AI in clinical trials",
        companyName: "Paradigm",
        marketValue: "NA",
        from: "Bristol-Myers Squibb",
        to: 291,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "K36 Therapeutics",
        marketValue: "70",
        from: "Bristol-Myers Squibb",
        to: 292,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene delivery vehicles ",
        companyName: "iVexSol",
        marketValue: "23.8",
        from: "Bristol-Myers Squibb",
        to: 293,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "Metagenomi Technologies",
        marketValue: "175",
        from: "Bristol-Myers Squibb",
        to: 294,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "Cajal Neuroscience",
        marketValue: "96",
        from: "Bristol-Myers Squibb",
        to: 295,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "ArsenalBio",
        marketValue: "220",
        from: "Bristol-Myers Squibb",
        to: 296,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Turning Point Therapeutics",
        marketValue: "4100",
        from: "Bristol-Myers Squibb",
        to: 297,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "BigHat Biosciences",
        marketValue: "75",
        from: "Bristol-Myers Squibb",
        to: 298,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "AI in clinical trials",
        companyName: "Owkin",
        marketValue: "180",
        from: "Bristol-Myers Squibb",
        to: 299,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Transition Bio",
        marketValue: "50",
        from: "Bristol-Myers Squibb",
        to: 300,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Sapience Therapeutics",
        marketValue: "41",
        from: "Bristol-Myers Squibb",
        to: 301,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Nuvig Therapeutics",
        marketValue: "47",
        from: "Bristol-Myers Squibb",
        to: 302,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Octant Bio",
        marketValue: "80",
        from: "Bristol-Myers Squibb",
        to: 303,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Ceptur Therapeutics",
        marketValue: "75",
        from: "Bristol-Myers Squibb",
        to: 304,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Compugen",
        marketValue: "20",
        from: "Bristol-Myers Squibb",
        to: 305,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein Degradation Therapy",
        companyName: "GlycoEra",
        marketValue: "NA",
        from: "Bristol-Myers Squibb",
        to: 306,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Nitrase Therapeutics",
        marketValue: "45",
        from: "Bristol-Myers Squibb",
        to: 307,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Treefrog Therapeutics",
        marketValue: "75",
        from: "Bristol-Myers Squibb",
        to: 308,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "Obsidian Therapeutics",
        marketValue: "NA",
        from: "Bristol-Myers Squibb",
        to: 309,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Cardior",
        marketValue: "76",
        from: "Bristol-Myers Squibb",
        to: 310,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "IMIDomics",
        marketValue: "16.5",
        from: "Bristol-Myers Squibb",
        to: 311,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "Allyx Therapeutics",
        marketValue: "NA",
        from: "Bristol-Myers Squibb",
        to: 312,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "HiberCell, Inc.",
        marketValue: "67.4",
        from: "Bristol-Myers Squibb",
        to: 313,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Exscientia",
        marketValue: "1375",
        from: "Bristol-Myers Squibb",
        to: 314,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Akamis Bio",
        marketValue: "NA",
        from: "Bristol-Myers Squibb",
        to: 315,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "MyoKardia",
        marketValue: "13100",
        from: "Bristol-Myers Squibb",
        to: 316,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Galecto",
        marketValue: "64",
        from: "Bristol-Myers Squibb",
        to: 317,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Forbius",
        marketValue: "NA",
        from: "Bristol-Myers Squibb",
        to: 318,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "SyncSense",
        marketValue: "NA",
        from: "Bristol-Myers Squibb",
        to: 319,
        sector: "Biotechnology ",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Repare Therapeutics",
        marketValue: "65",
        from: "Bristol-Myers Squibb",
        to: 320,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Silverback Therapeutics",
        marketValue: "78.5",
        from: "Bristol-Myers Squibb",
        to: 321,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "Celgene",
        marketValue: "7400",
        from: "Bristol-Myers Squibb",
        to: 322,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Alpha Cancer Technologies",
        marketValue: "NA",
        from: "Bristol-Myers Squibb",
        to: 323,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Microbiome-based therapies",
        companyName: "Vedanta Biosciences ",
        marketValue: "18.5",
        from: "Bristol-Myers Squibb",
        to: 324,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Ayala Pharmaceuticals",
        marketValue: "17",
        from: "Bristol-Myers Squibb",
        to: 325,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Microbiome-based therapies",
        companyName: "Enterome",
        marketValue: "38.5",
        from: "Bristol-Myers Squibb",
        to: 326,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "in vitro diagnostic (IVD) genome testing",
        companyName: "Personal Genome Diagnostics",
        marketValue: "75",
        from: "Bristol-Myers Squibb",
        to: 327,
        sector: "Biotechnology ",
    },
    {
        partnership: "Acquisition",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Ambrx",
        marketValue: "2000",
        from: "Johnson & Johnson",
        to: 328,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "Arkuda Therapeutics",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 329,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Elektrofi",
        marketValue: "173",
        from: "Johnson & Johnson",
        to: 330,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Minimal residual disease (MRD) testing",
        companyName: "Illumina Inc",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 331,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: " Nanotherapeutics",
        companyName: "Nanobiotix",
        marketValue: "1830",
        from: "Johnson & Johnson",
        to: 332,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Intraoperative molecular imaging",
        companyName: "On Target Laboratories",
        marketValue: "30",
        from: "Johnson & Johnson",
        to: 333,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Aro Biotherapeutics",
        marketValue: "41.5",
        from: "Johnson & Johnson",
        to: 334,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Intelligent OMICS Ltd.",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 335,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "LAVA Therapeutics",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 336,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: " Automated drug manufacturing technology",
        companyName: "Astraveus",
        marketValue: "18.1",
        from: "Johnson & Johnson",
        to: 337,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Investment",
        modality: "Robotic surgery",
        companyName: "Moon Surgical",
        marketValue: "55.4",
        from: "Johnson & Johnson",
        to: 338,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Non-invasive healthcare devices",
        companyName: "Solenic Medical ",
        marketValue: "5.1",
        from: "Johnson & Johnson",
        to: 339,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "ID Pharma",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 340,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName:
            "Contineum Therapeutics\n(Before named as Pipeline therapeutics)",
        marketValue: "1100",
        from: "Johnson & Johnson",
        to: 341,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "Rapport Therapeutics",
        marketValue: "150",
        from: "Johnson & Johnson",
        to: 342,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Biocytogen Pharmaceuticals",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 343,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "AI-powered diagnostics",
        companyName: "ArteraAI",
        marketValue: "90",
        from: "Johnson & Johnson",
        to: 344,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Non-invasive healthcare devices",
        companyName: "Prana Thoracic",
        marketValue: "3",
        from: "Johnson & Johnson",
        to: 345,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "MeiraGTx",
        marketValue: "415",
        from: "Johnson & Johnson",
        to: 346,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "LegoChem Biosciences",
        marketValue: "1800",
        from: "Johnson & Johnson",
        to: 347,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Mersana Therapeutics",
        marketValue: "1040",
        from: "Johnson & Johnson",
        to: 348,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Therapeutic devices",
        companyName: "Abiomed",
        marketValue: "16600",
        from: "Johnson & Johnson",
        to: 349,
        sector: "Biotechnology ",
    },
    {
        partnership: "Investment",
        modality: "Non-invasive healthcare devices",
        companyName: "HistoSonics",
        marketValue: "85",
        from: "Johnson & Johnson",
        to: 350,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Osteal Therapeutics",
        marketValue: "30",
        from: "Johnson & Johnson",
        to: 351,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "WuXi Advanced Therapies",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 352,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "AI-powered diagnostics",
        companyName: "Paige",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 353,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "Serotiny",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 354,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Hangzhou DAC Biotechnology",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 355,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "Locus Biosciences",
        marketValue: "35",
        from: "Johnson & Johnson",
        to: 356,
        sector: "Biotechnology ",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "VantAI",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 357,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Neuroscience Therapy",
        companyName: "Bioasis Technologies",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 358,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Bispecific antibodies",
        companyName: "Rondo Therapeutics",
        marketValue: "67",
        from: "Johnson & Johnson",
        to: 359,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Remix Therapeutics",
        marketValue: "1045",
        from: "Johnson & Johnson",
        to: 360,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "VerImmune",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 361,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Anakuria Therapeutics",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 362,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "AI in clinical trials",
        companyName: "Iterative Scopes ",
        marketValue: "150",
        from: "Johnson & Johnson",
        to: 363,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Intranasal spray medications ",
        companyName: "Leyden Labs",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 364,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Partnership",
        modality: "Ionic liquid technology",
        companyName: "i2o Therapeutics",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 365,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Partnership",
        modality: "Small molecule Therapy",
        companyName: "SRI International",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 366,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "TRexBio",
        marketValue: "59",
        from: "Johnson & Johnson",
        to: 367,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "AI in clinical trials",
        companyName: "Verana Health",
        marketValue: "150",
        from: "Johnson & Johnson",
        to: 368,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Therapeutic devices",
        companyName: "CrossRoads Extremity Systems",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 369,
        sector: "Biotechnology ",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "AviadoBio",
        marketValue: "80",
        from: "Johnson & Johnson",
        to: 370,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Small molecule Therapy",
        companyName: "Philogen ",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 371,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "AI-powered diagnostics",
        companyName: "Ultromics",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 372,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Active pharmaceutical ingredients (APIs)",
        companyName: "entrinsic bioscience",
        marketValue: "49",
        from: "Johnson & Johnson",
        to: 373,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Thirty Madison",
        marketValue: "140",
        from: "Johnson & Johnson",
        to: 374,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Cue Health",
        marketValue: "235",
        from: "Johnson & Johnson",
        to: 375,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Antiviral Conjugates (AVCs)",
        companyName: "Cidara Therapeutics",
        marketValue: "780",
        from: "Johnson & Johnson",
        to: 376,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "AI-powered diagnostics",
        companyName: "Techsomed",
        marketValue: "7",
        from: "Johnson & Johnson",
        to: 377,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Microbiome-based therapies",
        companyName: "Evolve BioSystems",
        marketValue: "55",
        from: "Johnson & Johnson",
        to: 378,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Morphic Therapeutic",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 379,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Bispecific antibodies",
        companyName: "Revitope Oncology ",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 380,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Bispecific antibodies",
        companyName: "Xencor",
        marketValue: "1313",
        from: "Johnson & Johnson",
        to: 381,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Microbiome-based therapies",
        companyName: "Persephone Biosciences",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 382,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Mestag Therapeutics ",
        marketValue: "45",
        from: "Johnson & Johnson",
        to: 383,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Therapeutic devices",
        companyName: "OrthoSpin ",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 384,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "ONL Therapeutics",
        marketValue: "61.9",
        from: "Johnson & Johnson",
        to: 385,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "MacroGenics",
        marketValue: "332",
        from: "Johnson & Johnson",
        to: 386,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "CHO Plus",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 387,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Symvivo Corporation",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 388,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Koa Health",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 389,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "ImmPACT Bio",
        marketValue: "18",
        from: "Johnson & Johnson",
        to: 390,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Microbiome-based therapies",
        companyName: "Dermala",
        marketValue: "6.73",
        from: "Johnson & Johnson",
        to: 391,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Datavant",
        marketValue: "40",
        from: "Johnson & Johnson",
        to: 392,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Therapeutic devices",
        companyName: "V-Wave",
        marketValue: "98",
        from: "Johnson & Johnson",
        to: 393,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Therapeutic devices",
        companyName: "GI Windows Medical Corp",
        marketValue: "16.4",
        from: "Johnson & Johnson",
        to: 394,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "XWPharma",
        marketValue: "40",
        from: "Johnson & Johnson",
        to: 395,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Aetion",
        marketValue: "19",
        from: "Johnson & Johnson",
        to: 396,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Envisagenics",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 397,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Radiopharmaceutical therapy",
        companyName: "RefleXion",
        marketValue: "100",
        from: "Johnson & Johnson",
        to: 398,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Partnership",
        modality: "RNA Therapeutics",
        companyName: "Exonate",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 399,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "ConcertAI",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 400,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Vor Biopharma",
        marketValue: "110",
        from: "Johnson & Johnson",
        to: 401,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: " Implantable medical device",
        companyName: "CVRx®",
        marketValue: "50",
        from: "Johnson & Johnson",
        to: 402,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Hemera Biosciences ",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 403,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Momenta Pharmaceuticals",
        marketValue: "6500",
        from: "Johnson & Johnson",
        to: 404,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Therapeutic devices",
        companyName: "Verb Surgical",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 405,
        sector: "Biotechnology ",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Taris Biomedical",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 406,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Acquisition",
        modality: "Robotic surgery",
        companyName: "Auris",
        marketValue: "5750",
        from: "Johnson & Johnson",
        to: 407,
        sector: "Biotechnology ",
    },
    {
        partnership: "Investment",
        modality: "Microbiome-based therapies",
        companyName: "Holobiome",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 408,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Therapeutic devices",
        companyName: "Emerging Implant Technologies (EIT)",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 409,
        sector: "Biotechnology ",
    },
    {
        partnership: "Acquisition",
        modality: "Robotic surgery",
        companyName: "Orthotaxy",
        marketValue: "NA",
        from: "Johnson & Johnson",
        to: 410,
        sector: "Biotechnology ",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Biohaven Pharmaceutical Holding Company Ltd.",
        marketValue: "11600",
        from: "Pfizer",
        to: 411,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Seagen",
        marketValue: "43000",
        from: "Pfizer",
        to: 412,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Vaccines",
        companyName: "BioNTech",
        marketValue: "748",
        from: "Pfizer",
        to: 413,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Caribou Biosciences",
        marketValue: "25",
        from: "Pfizer",
        to: 414,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing (ZFP)",
        companyName: "Sangamo Therapeutics",
        marketValue: "167",
        from: "Pfizer",
        to: 415,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Homology Medicines, Inc.",
        marketValue: "60",
        from: "Pfizer",
        to: 416,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "Beam Therapeutics Inc.",
        marketValue: "1350",
        from: "Pfizer",
        to: 417,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "CytoReason",
        marketValue: "110",
        from: "Pfizer",
        to: 418,
        sector: "Biotechnology",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "Global Blood Therapeutics",
        marketValue: "5400",
        from: "Pfizer",
        to: 419,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Gero.AI",
        marketValue: "NA",
        from: "Pfizer",
        to: 420,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "PostEra",
        marketValue: "261",
        from: "Pfizer",
        to: 421,
        sector: "Biotechnology",
    },
    {
        partnership: "Partnership",
        modality: "AI in clinical trials",
        companyName: "Tempus",
        marketValue: "NA",
        from: "Pfizer",
        to: 422,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Spero Therapeutics",
        marketValue: "120",
        from: "Pfizer",
        to: 423,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Ginkgo Bioworks",
        marketValue: "331",
        from: "Pfizer",
        to: 424,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "CellCentric",
        marketValue: "25",
        from: "Pfizer",
        to: 425,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Therachon Holding AG",
        marketValue: "810",
        from: "Pfizer",
        to: 426,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Microbiome-based therapies",
        companyName: "Vedanta Biosciences",
        marketValue: "25",
        from: "Pfizer",
        to: 427,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Herophilus (Formely System1 Biosciences)",
        marketValue: "25",
        from: "Pfizer",
        to: 428,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Voyager Therapeutics",
        marketValue: "630",
        from: "Pfizer",
        to: 429,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "Array BioPharma",
        marketValue: "11400",
        from: "Pfizer",
        to: 430,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Small molecule Therapy",
        companyName: "CSPC Pharmaceutical Group",
        marketValue: "NA",
        from: "Pfizer",
        to: 431,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Ribon Therapeutics",
        marketValue: "25",
        from: "Pfizer",
        to: 432,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "XtalPi Inc.",
        marketValue: "NA",
        from: "Pfizer",
        to: 433,
        sector: "Biotechnology",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Insilico Medicine",
        marketValue: "NA",
        from: "Pfizer",
        to: 434,
        sector: "Biotechnology",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Iktos",
        marketValue: "NA",
        from: "Pfizer",
        to: 435,
        sector: "Biotechnology",
    },
    {
        partnership: "Partnership",
        modality: "Polymer technology",
        companyName: "Serina Therapeutics, Inc.",
        marketValue: "NA",
        from: "Pfizer",
        to: 436,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Ada Health",
        marketValue: "NA",
        from: "Pfizer",
        to: 437,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Cue Health",
        marketValue: "NA",
        from: "Pfizer",
        to: 438,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Acquisition",
        modality: "Non-invasive healthcare devices",
        companyName: "Lucira Health",
        marketValue: "36.4",
        from: "Pfizer",
        to: 439,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "ORIC Pharmaceuticals",
        marketValue: "25",
        from: "Pfizer",
        to: 440,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Carrick Therapeutics",
        marketValue: "35",
        from: "Pfizer",
        to: 441,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Anokion",
        marketValue: "35",
        from: "Pfizer",
        to: 442,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Digital health tool",
        companyName: "ResApp Health",
        marketValue: "116",
        from: "Pfizer",
        to: 443,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "AgomAb Therapeutics",
        marketValue: "40.5",
        from: "Pfizer",
        to: 444,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Vaccines",
        companyName: "Valneva",
        marketValue: "95",
        from: "Pfizer",
        to: 445,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Akero Therapeutics",
        marketValue: "25",
        from: "Pfizer",
        to: 446,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Bispecific antibodies",
        companyName: "Dren Bio",
        marketValue: "1025",
        from: "Pfizer",
        to: 447,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Zentalis Pharmaceuticals",
        marketValue: "25",
        from: "Pfizer",
        to: 448,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "ReViral",
        marketValue: "525",
        from: "Pfizer",
        to: 449,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "Arena Pharmaceuticals",
        marketValue: "6700",
        from: "Pfizer",
        to: 450,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Cardiff Oncology",
        marketValue: "15",
        from: "Pfizer",
        to: 451,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Trillium Therapeutics",
        marketValue: "2220",
        from: "Pfizer",
        to: 452,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein Degradation Therapy",
        companyName: "Arvinas",
        marketValue: "2050",
        from: "Pfizer",
        to: 453,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Amplyx Pharmaceuticals",
        marketValue: "NA",
        from: "Pfizer",
        to: 454,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "ImCyse",
        marketValue: "25.8",
        from: "Pfizer",
        to: 455,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "LianBio",
        marketValue: "155",
        from: "Pfizer",
        to: 456,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "Arixa Pharmaceuticals",
        marketValue: "NA",
        from: "Pfizer",
        to: 457,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "CStone Pharmaceuticals",
        marketValue: "200",
        from: "Pfizer",
        to: 458,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Direct Lytic Agents (DLAs)",
        companyName: "ContraFect",
        marketValue: "3",
        from: "Pfizer",
        to: 459,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Vivet Therapeutics",
        marketValue: "651",
        from: "Pfizer",
        to: 460,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Gliknik",
        marketValue: "15",
        from: "Pfizer",
        to: 461,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Nona Biosciences",
        marketValue: "1103",
        from: "Pfizer",
        to: 462,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Vaccines",
        companyName: "BioNTech",
        marketValue: "425",
        from: "Pfizer",
        to: 463,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "ImmunOs Therapeutics AG",
        marketValue: "16.9",
        from: "Pfizer",
        to: 464,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Truveta",
        marketValue: "NA",
        from: "Pfizer",
        to: 465,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Ranok Therapeutics",
        marketValue: "NA",
        from: "Pfizer",
        to: 466,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Multiple modalities",
        companyName: "Anjarium Biosciences",
        marketValue: "61",
        from: "Pfizer",
        to: 467,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Mediar Therapeutics",
        marketValue: "NA",
        from: "Pfizer",
        to: 468,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Telesis Bio, Inc. (Formely Codex DNA)",
        marketValue: "100",
        from: "Pfizer",
        to: 469,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Multiple modalities",
        companyName: "SpringWorks Therapeutics",
        marketValue: "NA",
        from: "Pfizer",
        to: 470,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Montis Biosciences",
        marketValue: "9.02",
        from: "Pfizer",
        to: 471,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Imago BioSciences",
        marketValue: "20",
        from: "Pfizer",
        to: 472,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Microbiome-based therapies",
        companyName: "Adapsyn Bioscience",
        marketValue: "162",
        from: "Pfizer",
        to: 473,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Curve Therapeutics",
        marketValue: "52.05",
        from: "Pfizer",
        to: 474,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "DEM Biopharma",
        marketValue: "70",
        from: "Pfizer",
        to: 475,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Grey Wolf Therapeutics",
        marketValue: "49",
        from: "Pfizer",
        to: 476,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "ImCheck Therapeutics",
        marketValue: "101",
        from: "Pfizer",
        to: 477,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName:
            "Incendia Therapeutics\n\n(Previously known as Parthenon Therapeutics)",
        marketValue: "65",
        from: "Pfizer",
        to: 478,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Interius BioTherapeutics",
        marketValue: "76",
        from: "Pfizer",
        to: 479,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Jnana Therapeutics",
        marketValue: "107",
        from: "Pfizer",
        to: 480,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Kestrel Therapeutics",
        marketValue: "40",
        from: "Pfizer",
        to: 481,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Mission Therapeutics",
        marketValue: "15",
        from: "Pfizer",
        to: 482,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Nimbus Therapeutics",
        marketValue: "125",
        from: "Pfizer",
        to: 483,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "BlueRock Therapeutics",
        marketValue: "250",
        from: "Bayer",
        to: 484,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Gene therapy",
        companyName: "Asklepios BioPharmaceutical",
        marketValue: "4000",
        from: "Bayer",
        to: 485,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Gene therapy",
        companyName: "Acuitas Therapeutics, Inc.",
        marketValue: "NA",
        from: "Bayer",
        to: 486,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Triumvira Immunologics Inc",
        marketValue: "100",
        from: "Bayer",
        to: 487,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Targeted Alpha Therapies (TATs)",
        companyName: "Noria Therapeutics",
        marketValue: "NA",
        from: "Bayer",
        to: 488,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Drug development in Women’s Healthcare",
        companyName: " KaNDy Therapeutics Ltd",
        marketValue: "875",
        from: "Bayer",
        to: 489,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Drug development in Women’s Healthcare",
        companyName: "Systems Oncology",
        marketValue: "345",
        from: "Bayer",
        to: 490,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Gene editing technologies (CRISPR)",
        companyName:
            "Casebia Therapeutics (CRISPR Therapeutics and Bayer joint venture)",
        marketValue: "NA",
        from: "Bayer",
        to: 491,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "Metagenomi Technologies",
        marketValue: "65",
        from: "Bayer",
        to: 492,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Huma Therapeutics ",
        marketValue: "130",
        from: "Bayer",
        to: 493,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Ada Health",
        marketValue: "90",
        from: "Bayer",
        to: 494,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "One Drop",
        marketValue: "100",
        from: "Bayer",
        to: 495,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "Vesigen Therapeutics",
        marketValue: "28.5",
        from: "Bayer",
        to: 496,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Microbiome-based therapies",
        companyName: "Azitra Inc.",
        marketValue: "17",
        from: "Bayer",
        to: 497,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Microbiome-based therapies",
        companyName: "Bloom Science",
        marketValue: "12",
        from: "Bayer",
        to: 498,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Elly Health",
        marketValue: "1.3",
        from: "Bayer",
        to: 499,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Wellthy Therapeutics",
        marketValue: "NA",
        from: "Bayer",
        to: 500,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Visotec GmbH",
        marketValue: "0.081",
        from: "Bayer",
        to: 501,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Upside Health",
        marketValue: "0.2",
        from: "Bayer",
        to: 502,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Boundless Bio",
        marketValue: "100",
        from: "Bayer",
        to: 503,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Genomics analysis",
        companyName: "Paratus Sciences",
        marketValue: "100",
        from: "Bayer",
        to: 504,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Aparito",
        marketValue: "1.1",
        from: "Bayer",
        to: 505,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Agamon Health",
        marketValue: "3",
        from: "Bayer",
        to: 506,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Affini-T Therapeutics ",
        marketValue: "175",
        from: "Bayer",
        to: 507,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Indapta Therapeutics ",
        marketValue: "50",
        from: "Bayer",
        to: 508,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Woebot Health",
        marketValue: "9.5",
        from: "Bayer",
        to: 509,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Cellino",
        marketValue: "80",
        from: "Bayer",
        to: 510,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Deka Biosciences",
        marketValue: "20",
        from: "Bayer",
        to: 511,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "GRO Biosciences Inc.",
        marketValue: "25",
        from: "Bayer",
        to: 512,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Mozart Therapeutics",
        marketValue: "55",
        from: "Bayer",
        to: 513,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Edifice Health ",
        marketValue: "12",
        from: "Bayer",
        to: 514,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Therapeutics for Food allergy",
        companyName: "Ukko",
        marketValue: "40",
        from: "Bayer",
        to: 515,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Ji Xing Pharmaceuticals",
        marketValue: "35",
        from: "Bayer",
        to: 516,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Vividion Therapeutics",
        marketValue: "2000",
        from: "Bayer",
        to: 517,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Radiopharmaceutical therapy",
        companyName: "Ratio Therapeutics",
        marketValue: "20",
        from: "Bayer",
        to: 518,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Recursion",
        marketValue: "50",
        from: "Bayer",
        to: 519,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Non-invasive healthcare devices",
        companyName: "Acorai\n",
        marketValue: "NA",
        from: "Bayer",
        to: 520,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Vaccines",
        companyName: "Khloris Biosciences",
        marketValue: "NA",
        from: "Bayer",
        to: 521,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Dewpoint Therapeutics",
        marketValue: "100",
        from: "Bayer",
        to: 522,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Pyxis Oncology",
        marketValue: "22",
        from: "Bayer",
        to: 523,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Century Therapeutics",
        marketValue: "250",
        from: "Bayer",
        to: 524,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "eGenesis",
        marketValue: "50",
        from: "Bayer",
        to: 525,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Kojin Therapeutics",
        marketValue: "NA",
        from: "Bayer",
        to: 526,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Drug development in Women’s Healthcare",
        companyName: "Daré Bioscience",
        marketValue: "330",
        from: "Bayer",
        to: 527,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Gene therapy",
        companyName: "Viralgen Vector Core",
        marketValue: "4000",
        from: "Bayer",
        to: 528,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Gene therapy",
        companyName:
            "TAAV Biomanufacturing Solutions\n(Asklepios BioPharmaceutical and Touchlight)",
        marketValue: "NA",
        from: "Bayer",
        to: 529,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "AI-powered diagnostics",
        companyName: "Blackford Analysis Inc",
        marketValue: "NA",
        from: "Bayer",
        to: 530,
        sector: "Biotechnology",
    },
    {
        partnership: "Acquisition",
        modality: "Gene therapy",
        companyName: "Brain Neurotherapy Bio, Inc",
        marketValue: "NA",
        from: "Bayer",
        to: 531,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Aqemia",
        marketValue: "140",
        from: "Sanofi",
        to: 532,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "MeiraGTx",
        marketValue: "30",
        from: "Sanofi",
        to: 533,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "QurAlis Corporation",
        marketValue: "88",
        from: "Sanofi",
        to: 534,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Formation Bio (Formely TrialSpark )",
        marketValue: "NA",
        from: "Sanofi",
        to: 535,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Innate Pharma",
        marketValue: "1456.4",
        from: "Sanofi",
        to: 536,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Vaccines",
        companyName: "Janssen Pharmaceuticals",
        marketValue: "175",
        from: "Sanofi",
        to: 537,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "Kiadis Pharma",
        marketValue: "358",
        from: "Sanofi",
        to: 538,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "Scribe Therapeutics",
        marketValue: "1025",
        from: "Sanofi",
        to: 539,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Provention Bio",
        marketValue: "2900",
        from: "Sanofi",
        to: 540,
        sector: "Drug discovery and Development ",
    },
    {
        partnership: "Acquisition",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Kadmon Corporation",
        marketValue: "1900",
        from: "Sanofi",
        to: 541,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Exscientia",
        marketValue: "5300",
        from: "Sanofi",
        to: 542,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "BioMap",
        marketValue: "1010",
        from: "Sanofi",
        to: 543,
        sector: "Biotechnology",
    },
    {
        partnership: "Acquisition",
        modality: "Microbiome-based therapies",
        companyName: "Origimm Biotechnology",
        marketValue: "NA",
        from: "Sanofi",
        to: 544,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "RNA Therapeutics",
        companyName: "Tidal Therapeutics",
        marketValue: "470",
        from: "Sanofi",
        to: 545,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Enable Injections",
        marketValue: "50",
        from: "Sanofi",
        to: 546,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Kymab Limited",
        marketValue: "1450",
        from: "Sanofi",
        to: 547,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "NovAliX",
        marketValue: "NA",
        from: "Sanofi",
        to: 548,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Teva Pharmaceuticals",
        marketValue: "500",
        from: "Sanofi",
        to: 549,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "RNA Therapeutics",
        companyName: "Translate Bio",
        marketValue: "3200",
        from: "Sanofi",
        to: 550,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Curadigm",
        marketValue: "NA",
        from: "Sanofi",
        to: 551,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Click Therapeutics",
        marketValue: "17",
        from: "Sanofi",
        to: 552,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "BioMed X",
        marketValue: "NA",
        from: "Sanofi",
        to: 553,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Massachusetts Institute of Technology (MIT)",
        marketValue: "25",
        from: "Sanofi",
        to: 554,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Recludix Pharma",
        marketValue: "1325",
        from: "Sanofi",
        to: 555,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Inhibrx Inc",
        marketValue: "1700",
        from: "Sanofi",
        to: 556,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Areteia Therapeutics",
        marketValue: "350",
        from: "Sanofi",
        to: 557,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Amunix Pharmaceuticals Inc",
        marketValue: "1225",
        from: "Sanofi",
        to: 558,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Owkin",
        marketValue: "270",
        from: "Sanofi",
        to: 559,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "AI in clinical trials",
        companyName: "Novadiscovery",
        marketValue: "2.6",
        from: "Sanofi",
        to: 560,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "Principia Biopharma",
        marketValue: "3680",
        from: "Sanofi",
        to: 561,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Translate Bio",
        marketValue: "425",
        from: "Sanofi",
        to: 562,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Kymera Therapeutics Inc",
        marketValue: "2150",
        from: "Sanofi",
        to: 563,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Synthorx, Inc.",
        marketValue: "2500",
        from: "Sanofi",
        to: 564,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Nurix Therapeutics",
        marketValue: "2555",
        from: "Sanofi",
        to: 565,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "AI in clinical trials",
        companyName: "Aetion",
        marketValue: "27",
        from: "Sanofi",
        to: 566,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Denali Therapeutics",
        marketValue: "1125",
        from: "Sanofi",
        to: 567,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Ablynx",
        marketValue: "4200",
        from: "Sanofi",
        to: 568,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Bioverativ",
        marketValue: "11600",
        from: "Sanofi",
        to: 569,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Ionic liquid technology",
        companyName: "i2O Therapeutics",
        marketValue: "NA",
        from: "Sanofi",
        to: 570,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Sudo Biosciences",
        marketValue: "116",
        from: "Sanofi",
        to: 571,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "IGM Biosciences",
        marketValue: "6150",
        from: "Sanofi",
        to: 572,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Gene therapy",
        companyName: "SIRION Biotech GmbH",
        marketValue: "NA",
        from: "Sanofi",
        to: 573,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Biond Biologics",
        marketValue: "1125",
        from: "Sanofi",
        to: 574,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Adagene",
        marketValue: "2517.5",
        from: "Sanofi",
        to: 575,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Bispecific antibodies",
        companyName: "ABL Bio",
        marketValue: "1060",
        from: "Sanofi",
        to: 576,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Therapeutic devices",
        companyName: "BIOCORP",
        marketValue: "8.07",
        from: "Sanofi",
        to: 577,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Health2Sync",
        marketValue: "NA",
        from: "Sanofi",
        to: 578,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "BrightInsight Inc",
        marketValue: "NA",
        from: "Sanofi",
        to: 579,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Eligo Bioscience",
        marketValue: "30",
        from: "Sanofi",
        to: 580,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Q32 Bio Inc.",
        marketValue: "42",
        from: "Sanofi",
        to: 581,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "T-Therapeutics",
        marketValue: "59",
        from: "Sanofi",
        to: 582,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Vaccines",
        companyName: "MinervaX",
        marketValue: "57",
        from: "Sanofi",
        to: 583,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Monoclonal Antibody",
        companyName: "Abcuro, Inc.",
        marketValue: "42",
        from: "Sanofi",
        to: 584,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Tisento Therapeutics",
        marketValue: "81",
        from: "Sanofi",
        to: 585,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "VERALOX Therapeutics Inc.",
        marketValue: "5.4",
        from: "Sanofi",
        to: 586,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Monoclonal Antibody",
        companyName: "Eledon Pharmaceuticals, Inc.",
        marketValue: "185",
        from: "Sanofi",
        to: 587,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein Degradation Therapy",
        companyName: "Avilar Therapeutics",
        marketValue: "75",
        from: "Sanofi",
        to: 588,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Escient Pharmaceuticals",
        marketValue: "120",
        from: "Sanofi",
        to: 589,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: " Normunity, Inc",
        marketValue: "65",
        from: "Sanofi",
        to: 590,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Matchpoint Therapeutics",
        marketValue: "70",
        from: "Sanofi",
        to: 591,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Skyhawk Therapeutics Inc.",
        marketValue: "2054",
        from: "Sanofi",
        to: 592,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Generation Bio",
        marketValue: "76",
        from: "Moderna",
        to: 593,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Vaccines",
        companyName: "OriCiro Genomics",
        marketValue: "85",
        from: "Moderna",
        to: 594,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Partnership",
        modality: "Vaccines",
        companyName: "Novocol Pharma",
        marketValue: "NA",
        from: "Moderna",
        to: 595,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Monash University",
        marketValue: "3",
        from: "Moderna",
        to: 596,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "CytomX",
        marketValue: "1235",
        from: "Moderna",
        to: 597,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "RNA Therapeutics",
        companyName: "Life Edit Therapeutics",
        marketValue: "NA",
        from: "Moderna",
        to: 598,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Carisma Therapeutics Inc.",
        marketValue: "45",
        from: "Moderna",
        to: 599,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Immatics",
        marketValue: "120",
        from: "Moderna",
        to: 600,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "Metagenomi",
        marketValue: "NA",
        from: "Moderna",
        to: 601,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Caris Life Sciences",
        marketValue: "NA",
        from: "Moderna",
        to: 602,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Vaccines",
        companyName: "University of Queensland",
        marketValue: "NA",
        from: "Moderna",
        to: 603,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "RNA Therapeutics",
        companyName: "University of Toronto",
        marketValue: "NA",
        from: "Moderna",
        to: 604,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "RNA Therapeutics",
        companyName: "McGill University",
        marketValue: "NA",
        from: "Moderna",
        to: 605,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "CARsgen Therapeutics",
        marketValue: "NA",
        from: "Moderna",
        to: 606,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Vaccines",
        companyName: "Aldevron",
        marketValue: "NA",
        from: "Moderna",
        to: 607,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Partnership",
        modality: "RNA Therapeutics",
        companyName: "AbCellera",
        marketValue: "NA",
        from: "Moderna",
        to: 608,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "IBM",
        marketValue: "NA",
        from: "Moderna",
        to: 609,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Gandeeva Therapeutics, Inc.",
        marketValue: "NA",
        from: "Moderna",
        to: 610,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Harbour BioMed",
        marketValue: "NA",
        from: "Moderna",
        to: 611,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Microbiome-based therapies",
        companyName: "T3 Pharmaceuticals",
        marketValue: "517.5",
        from: "Boehringer Ingelheim",
        to: 612,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "Minerva Neurosciences",
        marketValue: "20",
        from: "Boehringer Ingelheim",
        to: 613,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cytokine-based therapeutics",
        companyName: "Trutino Biosciences",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 614,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antimicrobial Resistance (AMR)",
        companyName: "Aurobac Therapeutics",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 615,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Abexxa Biologics",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 616,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "Labor Dr. Merk & Kollegen",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 617,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "NBE Therapeutics",
        marketValue: "1300",
        from: "Boehringer Ingelheim",
        to: 618,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Northern Biologics",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 619,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Enleofen",
        marketValue: "1000",
        from: "Boehringer Ingelheim",
        to: 620,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Vaccines",
        companyName: "Amal Therapeutics",
        marketValue: "357",
        from: "Boehringer Ingelheim",
        to: 621,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Dendrimer-based drug delivery",
        companyName: "ICD Therapeutics",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 622,
        sector: "Drug delivery technology",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "ViraTherapeutics",
        marketValue: "231",
        from: "Boehringer Ingelheim",
        to: 623,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Cognizant",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 624,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Ribocure Pharmaceuticals AB",
        marketValue: "2000",
        from: "Boehringer Ingelheim",
        to: 625,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "PhoreMost Limited",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 626,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Rinri Therapeutics",
        marketValue: "13",
        from: "Boehringer Ingelheim",
        to: 627,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Oxford BioTherapeutics",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 628,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Ginkgo Bioworks",
        marketValue: "406",
        from: "Boehringer Ingelheim",
        to: 629,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Oxford Biomedica",
        marketValue: "36.7",
        from: "Boehringer Ingelheim",
        to: 630,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Cure Genetics",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 631,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Phenomic AI",
        marketValue: "509",
        from: "Boehringer Ingelheim",
        to: 632,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Ten63 Therapeutics",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 633,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Gubra",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 634,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Anagenesis Biotechnologies",
        marketValue: "3.3",
        from: "Boehringer Ingelheim",
        to: 635,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Surrozen, Inc.",
        marketValue: "599",
        from: "Boehringer Ingelheim",
        to: 636,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Therapeutic devices",
        companyName: "Autigen",
        marketValue: "100",
        from: "Boehringer Ingelheim",
        to: 637,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Inflammasome Therapeutics",
        marketValue: "160",
        from: "Boehringer Ingelheim",
        to: 638,
        sector: "Drug delivery technology",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "PureTech Health",
        marketValue: "226",
        from: "Boehringer Ingelheim",
        to: 639,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Microbiome-based therapies",
        companyName: "BiomX",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 640,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Evox Therapeutics",
        marketValue: "45.4",
        from: "Boehringer Ingelheim",
        to: 641,
        sector: "Drug delivery technology",
    },
    {
        partnership: "Investment",
        modality: "Regenerative medicine",
        companyName: "Exogenus Therapeutics",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 642,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Regenerative medicine",
        companyName: "EvoBiotiX SA",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 643,
        sector: "Drug delivery technology",
    },
    {
        partnership: "Investment",
        modality: "3D printing technology",
        companyName: "Triastek Inc.",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 644,
        sector: "Drug delivery technology",
    },
    {
        partnership: "Partnership",
        modality: "Genomics analysis",
        companyName: "IBM",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 645,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "3T Biosciences",
        marketValue: "538.5",
        from: "Boehringer Ingelheim",
        to: 646,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Click Therapeutics",
        marketValue: "500",
        from: "Boehringer Ingelheim",
        to: 647,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Partnership",
        modality: "AI-powered diagnostics",
        companyName: "Google",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 648,
        sector: "Biotechnology ",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Twist Bioscience",
        marketValue: "700",
        from: "Boehringer Ingelheim",
        to: 649,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein Degradation Therapy",
        companyName: "Proxygen",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 650,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Glox Therapeutics",
        marketValue: "5.6",
        from: "Boehringer Ingelheim",
        to: 651,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Actym Therapeutics",
        marketValue: "59.5",
        from: "Boehringer Ingelheim",
        to: 652,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Genomics analysis",
        companyName: "Thermo Fisher Scientific",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 653,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Covant Therapeutics",
        marketValue: "481",
        from: "Boehringer Ingelheim",
        to: 654,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antimicrobial Resistance (AMR)",
        companyName: "Obulytix",
        marketValue: "4.4",
        from: "Boehringer Ingelheim",
        to: 655,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Smartbax",
        marketValue: "1.3",
        from: "Boehringer Ingelheim",
        to: 656,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "DiogenX",
        marketValue: "30",
        from: "Boehringer Ingelheim",
        to: 657,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "C-mo Medical Solutions",
        marketValue: "4.8",
        from: "Boehringer Ingelheim",
        to: 658,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "Rewind Therapeutics",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 659,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Rgenta Therapeutics",
        marketValue: "20",
        from: "Boehringer Ingelheim",
        to: 660,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Nuevocor",
        marketValue: "24",
        from: "Boehringer Ingelheim",
        to: 661,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "AI-powered diagnostics",
        companyName: "Aignostics",
        marketValue: "5.5",
        from: "Boehringer Ingelheim",
        to: 662,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "AgomAb Therapeutics",
        marketValue: "23",
        from: "Boehringer Ingelheim",
        to: 663,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "ImCheck Therapeutics",
        marketValue: "103",
        from: "Boehringer Ingelheim",
        to: 664,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "ArrePath",
        marketValue: "20",
        from: "Boehringer Ingelheim",
        to: 665,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antimicrobial Resistance (AMR)",
        companyName: "Centauri Therapeutics",
        marketValue: "32",
        from: "Boehringer Ingelheim",
        to: 666,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "AI-powered diagnostics",
        companyName: "Brainomix",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 667,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "OncoMyx Therapeutics",
        marketValue: "25",
        from: "Boehringer Ingelheim",
        to: 668,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Asgard Therapeutics",
        marketValue: "6.6",
        from: "Boehringer Ingelheim",
        to: 669,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Genomics analysis",
        companyName: "Optina Diagnostics",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 670,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Abalos Therapeutics",
        marketValue: "50",
        from: "Boehringer Ingelheim",
        to: 671,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Eyevensys",
        marketValue: "30",
        from: "Boehringer Ingelheim",
        to: 672,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Dopavision",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 673,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Partnership",
        modality: "Protein Degradation Therapy",
        companyName: "Topas Therapeutics",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 674,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Vaccines",
        companyName: "Delonix Bioworks",
        marketValue: "14",
        from: "Boehringer Ingelheim",
        to: 675,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Perfood",
        marketValue: "5.5",
        from: "Boehringer Ingelheim",
        to: 676,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Libra Therapeutics",
        marketValue: "29",
        from: "Boehringer Ingelheim",
        to: 677,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Bodyport",
        marketValue: "11.2",
        from: "Boehringer Ingelheim",
        to: 678,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "T-Knife Therapeutics",
        marketValue: "72.6",
        from: "Boehringer Ingelheim",
        to: 679,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Small molecule Therapy",
        companyName: "QUANTRO Therapeutics",
        marketValue: "NA",
        from: "Boehringer Ingelheim",
        to: 680,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Wellth",
        marketValue: "10",
        from: "Boehringer Ingelheim",
        to: 681,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Tacalyx",
        marketValue: "7.7",
        from: "Boehringer Ingelheim",
        to: 682,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Acousia Therapeutics",
        marketValue: "11",
        from: "Boehringer Ingelheim",
        to: 683,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Aiolos Bio",
        marketValue: "1400",
        from: "GSK",
        to: 684,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antiviral Conjugates (AVCs)",
        companyName:
            "University of Alberta's Li Ka Shing Institute of Virology (LKSIoV)",
        marketValue: "1.5",
        from: "GSK",
        to: 1163,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "Bellus Health",
        marketValue: "2000",
        from: "GSK",
        to: 685,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "WaVe Life Sciences",
        marketValue: "3700",
        from: "GSK",
        to: 686,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Spero Therapeutics",
        marketValue: "600",
        from: "GSK",
        to: 687,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Vaccines",
        companyName: "Affinivax",
        marketValue: "3300",
        from: "GSK",
        to: 688,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Sierra Oncology",
        marketValue: "1900",
        from: "GSK",
        to: 689,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Genomics analysis",
        companyName: "LifeMine",
        marketValue: "70",
        from: "GSK",
        to: 690,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "IDEAYA Biosciences Inc.",
        marketValue: "170",
        from: "GSK",
        to: 691,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Vaccines",
        companyName: "CureVac",
        marketValue: "165",
        from: "GSK",
        to: 692,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "Sitari Pharmaceuticals",
        marketValue: "NA",
        from: "GSK",
        to: 693,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Combination Therapy",
        companyName: "SpringWorks Therapeutics",
        marketValue: "75",
        from: "GSK",
        to: 694,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "Tesaro",
        marketValue: "5100",
        from: "GSK",
        to: 695,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Sitryx",
        marketValue: "30",
        from: "GSK",
        to: 696,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Small molecule Therapy",
        companyName: "Fulrum Therapeutics",
        marketValue: "NA",
        from: "GSK",
        to: 697,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Genomics analysis",
        companyName: "23andMe",
        marketValue: "20",
        from: "GSK",
        to: 698,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Gene therapy",
        companyName: "Orchard Therapeutics",
        marketValue: "NA",
        from: "GSK",
        to: 699,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Liquidia Technologies",
        marketValue: "NA",
        from: "GSK",
        to: 700,
        sector: "Drug delivery technology",
    },
    {
        partnership: "Investment",
        modality: "Therapeutic devices",
        companyName: "NeuroMetrix",
        marketValue: "26.5",
        from: "GSK",
        to: 701,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Vaccines",
        companyName: "BioPIPS",
        marketValue: "NA",
        from: "GSK",
        to: 702,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Partnership",
        modality: "Nanotherapeutics",
        companyName: "imec",
        marketValue: "NA",
        from: "GSK",
        to: 703,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "iTeos Therapeutics",
        marketValue: "2045",
        from: "GSK",
        to: 704,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "Cell and Gene therapy Catapult (CGT Catapult)",
        marketValue: "NA",
        from: "GSK",
        to: 705,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Adrestia Therapeutics",
        marketValue: "1150",
        from: "GSK",
        to: 706,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "AI in clinical trials",
        companyName: "NVIDIA",
        marketValue: "NA",
        from: "GSK",
        to: 707,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "TB Alliance",
        marketValue: "NA",
        from: "GSK",
        to: 708,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Tempus",
        marketValue: "70",
        from: "GSK",
        to: 709,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "University of California",
        marketValue: "67",
        from: "GSK",
        to: 710,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "AI-powered diagnostics",
        companyName: "PathAI",
        marketValue: "NA",
        from: "GSK",
        to: 711,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Exscientia",
        marketValue: "NA",
        from: "GSK",
        to: 712,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "Alector",
        marketValue: "2200",
        from: "GSK",
        to: 713,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Halozyme Therapeutics",
        marketValue: "215",
        from: "GSK",
        to: 714,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Vaccines",
        companyName: "Vir Biotechnology",
        marketValue: "250",
        from: "GSK",
        to: 715,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Genomics analysis",
        companyName: "Promega Corporation",
        marketValue: "NA",
        from: "GSK",
        to: 716,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Oligonucleotide Therapeutics",
        companyName: "Elsie Biotechnologies, Inc.",
        marketValue: "NA",
        from: "GSK",
        to: 717,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "National University Corporation Kyushu University",
        marketValue: "NA",
        from: "GSK",
        to: 718,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Solu Therapeutics",
        marketValue: "NA",
        from: "GSK",
        to: 719,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "Presidio Medical",
        marketValue: "72",
        from: "GSK",
        to: 720,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "Saluda Medical",
        marketValue: "150",
        from: "GSK",
        to: 721,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Therapeutic devices",
        companyName: "SetPoint Medical",
        marketValue: "80",
        from: "GSK",
        to: 722,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "AI-powered diagnostics",
        companyName: "Onc.AI",
        marketValue: "25",
        from: "GSK",
        to: 723,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Therapeutic devices",
        companyName: "MicroTransponder",
        marketValue: "73",
        from: "GSK",
        to: 724,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Therapeutic devices",
        companyName: "Alpheus Medical",
        marketValue: "16",
        from: "GSK",
        to: 725,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Therapeutic devices",
        companyName: "Cala Health",
        marketValue: "50",
        from: "GSK",
        to: 726,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Therapeutic devices",
        companyName: "Neuspera",
        marketValue: "65",
        from: "GSK",
        to: 727,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Non-invasive healthcare devices",
        companyName: "Exo",
        marketValue: "40",
        from: "GSK",
        to: 728,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Therapeutic devices",
        companyName: "CVRx",
        marketValue: "50",
        from: "GSK",
        to: 729,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Acquisition",
        modality: "Automated drug manufacturing technology",
        companyName: "Erbi Biosystems",
        marketValue: "NA",
        from: "Merck KGaA",
        to: 730,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Acquisition",
        modality: "Neuroscience Therapy",
        companyName: "Chord Therapeutics",
        marketValue: "NA",
        from: "Merck KGaA",
        to: 731,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Implantable medical device",
        companyName: "INBRAIN Neuroelectronics",
        marketValue: "NA",
        from: "Merck KGaA",
        to: 732,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Acquisition",
        modality: "RNA Therapeutics",
        companyName: "AmpTec",
        marketValue: "NA",
        from: "Merck KGaA",
        to: 733,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Oligonucleotide Therapeutics",
        companyName: "DNA Script",
        marketValue: "89",
        from: "Merck KGaA",
        to: 734,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Syntropy",
        marketValue: "NA",
        from: "Merck KGaA",
        to: 735,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Acquisition",
        modality: "Automated drug manufacturing technology",
        companyName: "Resolution Spectra Systems",
        marketValue: "NA",
        from: "Merck KGaA",
        to: 736,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "Calporta Therapeutics",
        marketValue: "576",
        from: "Merck KGaA",
        to: 737,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "Flodesign Sonics",
        marketValue: "NA",
        from: "Merck KGaA",
        to: 738,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Akili Labs",
        marketValue: "160",
        from: "Merck KGaA",
        to: 739,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Acquisition",
        modality: "Digital health tool",
        companyName: "BSSN Software",
        marketValue: "NA",
        from: "Merck KGaA",
        to: 740,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Acquisition",
        modality: "Digital health tool",
        companyName: "ConnectMed",
        marketValue: "NA",
        from: "Merck KGaA",
        to: 741,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Sutro Biopharma",
        marketValue: "NA",
        from: "Merck KGaA",
        to: 742,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "STORM Therapeutics",
        marketValue: "30",
        from: "Merck KGaA",
        to: 743,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "DISCO Pharmaceuticals",
        marketValue: "22",
        from: "Merck KGaA",
        to: 744,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Nouscom",
        marketValue: "74.3",
        from: "Merck KGaA",
        to: 745,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "CellFE",
        marketValue: "22",
        from: "Merck KGaA",
        to: 746,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Astraveus",
        marketValue: "18.2",
        from: "Merck KGaA",
        to: 747,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Anavo Therapeutics",
        marketValue: "31",
        from: "Merck KGaA",
        to: 748,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Iktos",
        marketValue: "17",
        from: "Merck KGaA",
        to: 749,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "ImmuneBridge",
        marketValue: "12",
        from: "Merck KGaA",
        to: 750,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "AI-powered diagnostics",
        companyName: "Pictor Labs",
        marketValue: "18.8",
        from: "Merck KGaA",
        to: 751,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "NanoSyrinx",
        marketValue: "8",
        from: "Merck KGaA",
        to: 752,
        sector: "Drug delivery technology",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Sonde Health",
        marketValue: "16",
        from: "Merck KGaA",
        to: 753,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "Altoida",
        marketValue: "20.3",
        from: "Merck KGaA",
        to: 754,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Microbiome-based therapies",
        companyName: "Concerto Biosciences",
        marketValue: "23",
        from: "Merck KGaA",
        to: 755,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein Degradation Therapy",
        companyName: "Plexium",
        marketValue: "102",
        from: "Merck KGaA",
        to: 756,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "AI-powered diagnostics",
        companyName: "Future Fertility",
        marketValue: "NA",
        from: "Merck KGaA",
        to: 757,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "iOmx Therapeutics",
        marketValue: "75.3",
        from: "Merck KGaA",
        to: 758,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Theolytics",
        marketValue: "6.8",
        from: "Merck KGaA",
        to: 759,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Akili Interactive",
        marketValue: "160",
        from: "Merck KGaA",
        to: 760,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "iOnctura",
        marketValue: "16.5",
        from: "Merck KGaA",
        to: 761,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Scipio Bioscience",
        marketValue: "6.6",
        from: "Merck KGaA",
        to: 762,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Neurable",
        marketValue: "6",
        from: "Merck KGaA",
        to: 763,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Riffyn",
        marketValue: "15",
        from: "Merck KGaA",
        to: 764,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Ribometrix",
        marketValue: "30",
        from: "Merck KGaA",
        to: 765,
        sector: "Drug discovery and Development ",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "ApoGen Biotechnologies",
        marketValue: "4",
        from: "Merck KGaA",
        to: 766,
        sector: "Drug discovery and Development ",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Jiangsu Hengrui Pharmaceuticals",
        marketValue: "1540",
        from: "Merck KGaA",
        to: 767,
        sector: "Drug discovery and Development ",
    },
    {
        partnership: "Partnership",
        modality: "AI-powered diagnostics",
        companyName: "Quris-AI",
        marketValue: "NA",
        from: "Merck KGaA",
        to: 768,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "XtalPi Inc.",
        marketValue: "NA",
        from: "Merck KGaA",
        to: 769,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "Ovizio Imaging Systems",
        marketValue: "NA",
        from: "Merck KGaA",
        to: 770,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "NKMax",
        marketValue: "NA",
        from: "Merck KGaA",
        to: 771,
        sector: "Drug discovery and Development ",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Exscientia",
        marketValue: "674",
        from: "Merck KGaA",
        to: 772,
        sector: "Drug discovery and Development ",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Aqilion AB",
        marketValue: "1056",
        from: "Merck KGaA",
        to: 773,
        sector: "Drug discovery and Development ",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Inspirna, Inc.",
        marketValue: "45",
        from: "Merck KGaA",
        to: 774,
        sector: "Drug discovery and Development ",
    },
    {
        partnership: "Investment",
        modality: "Automated drug manufacturing technology",
        companyName: "Lonza",
        marketValue: "NA",
        from: "Merck KGaA",
        to: 775,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Acquisition",
        modality: "RNA Therapeutics",
        companyName: "Exelead",
        marketValue: "780",
        from: "Merck KGaA",
        to: 776,
        sector: "Drug manufacturing",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Huma Therapeutics",
        marketValue: "NA",
        from: "Merck KGaA",
        to: 777,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Autolus Therapeutics",
        marketValue: "200",
        from: "BioNTech",
        to: 778,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "CellmAbs",
        marketValue: "1000",
        from: "BioNTech",
        to: 779,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "RNA Therapeutics",
        companyName: "AexeRNA Therapeutics ",
        marketValue: "NA",
        from: "BioNTech",
        to: 780,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Partnership",
        modality: "Multiple modalities",
        companyName: "Koç University",
        marketValue: "NA",
        from: "BioNTech",
        to: 781,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "OncoC4",
        marketValue: "200",
        from: "BioNTech",
        to: 782,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "MediLink Therapeutics",
        marketValue: "1070",
        from: "BioNTech",
        to: 783,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Multiple modalities",
        companyName: "UK Government",
        marketValue: "NA",
        from: "BioNTech",
        to: 784,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Vaccines",
        companyName: "Victorian Government",
        marketValue: "NA",
        from: "BioNTech",
        to: 785,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Bispecific antibodies",
        companyName: "Biotheus Inc.",
        marketValue: "1055",
        from: "BioNTech",
        to: 786,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "In-silico drug discovery",
        companyName: "InstaDeep ",
        marketValue: "542",
        from: "BioNTech",
        to: 787,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Crescendo Biologics",
        marketValue: "822",
        from: "BioNTech",
        to: 788,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Duality Biologics",
        marketValue: "1670",
        from: "BioNTech",
        to: 789,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Medigene",
        marketValue: "28",
        from: "BioNTech",
        to: 790,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Ryvu Therapeutics",
        marketValue: "43",
        from: "BioNTech",
        to: 791,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Vaccines",
        companyName: "Matinas BioPharma",
        marketValue: "2.75",
        from: "BioNTech",
        to: 792,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Acquisition",
        modality: "Microbiome-based therapies",
        companyName: "PhagoMed",
        marketValue: "140",
        from: "BioNTech",
        to: 793,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "Neon Therapeutics",
        marketValue: "67",
        from: "BioNTech",
        to: 794,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "RNA Therapeutics",
        companyName: "Lipocalyx",
        marketValue: "7.65",
        from: "BioNTech",
        to: 795,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "MAB Discovery",
        marketValue: "NA",
        from: "BioNTech",
        to: 796,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "MabVax Therapeutics",
        marketValue: "NA",
        from: "BioNTech",
        to: 797,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "Kite- (a Gilead Company)",
        marketValue: "NA",
        from: "BioNTech",
        to: 798,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "RNA Therapeutics",
        companyName: "Regeneron",
        marketValue: "NA",
        from: "BioNTech",
        to: 799,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antiretroviral therapy",
        companyName: "Bill & Melinda Gates Foundation",
        marketValue: "100",
        from: "BioNTech",
        to: 800,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "RNA Therapeutics",
        companyName: "Genevant Sciences",
        marketValue: "NA",
        from: "BioNTech",
        to: 801,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Partnership",
        modality: "Vaccines",
        companyName: "University of Pennsylvania",
        marketValue: "NA",
        from: "BioNTech",
        to: 802,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "CymaBay Therapeutics",
        marketValue: "4300",
        from: "Gilead Sciences",
        to: 803,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Multiple modalities",
        companyName: "Arcus Biosciences",
        marketValue: "2750",
        from: "Gilead Sciences",
        to: 804,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Kyverna Therapeutics",
        marketValue: "732.5",
        from: "Gilead Sciences",
        to: 805,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Tentarix Biotherapeutics",
        marketValue: "66",
        from: "Gilead Sciences",
        to: 806,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "XinThera",
        marketValue: "NA",
        from: "Gilead Sciences",
        to: 807,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Compugen",
        marketValue: "848",
        from: "Gilead Sciences",
        to: 808,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Epic Bio",
        marketValue: "NA",
        from: "Gilead Sciences",
        to: 809,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antiviral Conjugates (AVCs)",
        companyName: "Assembly Biosciences",
        marketValue: "1075",
        from: "Gilead Sciences",
        to: 810,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "Tmunity Therapeutics ",
        marketValue: "NA",
        from: "Gilead Sciences",
        to: 811,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Nanotherapeutics",
        companyName: "EVOQ Therapeutics",
        marketValue: "658.5",
        from: "Gilead Sciences",
        to: 812,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "MiroBio",
        marketValue: "405",
        from: "Gilead Sciences",
        to: 813,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antiviral Conjugates (AVCs)",
        companyName: "Exavir Therapeutics",
        marketValue: "4",
        from: "Gilead Sciences",
        to: 814,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "AI in clinical trials",
        companyName: "Curebase",
        marketValue: "40",
        from: "Gilead Sciences",
        to: 815,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Arcellx",
        marketValue: "325",
        from: "Gilead Sciences",
        to: 816,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Refuge Biotechnologies",
        marketValue: "NA",
        from: "Gilead Sciences",
        to: 817,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antiviral Conjugates (AVCs)",
        companyName: "Pardes Biosciences",
        marketValue: "75",
        from: "Gilead Sciences",
        to: 818,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Vaccines",
        companyName: "Gritstone bio",
        marketValue: "785",
        from: "Gilead Sciences",
        to: 819,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Appia Bio",
        marketValue: "875",
        from: "Gilead Sciences",
        to: 820,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Vaccines",
        companyName: "Barinthus Biotherapeutics",
        marketValue: "168",
        from: "Gilead Sciences",
        to: 821,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Shoreline Biosciences",
        marketValue: "2300",
        from: "Gilead Sciences",
        to: 822,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "Oxford BioTherapeutics",
        marketValue: "NA",
        from: "Gilead Sciences",
        to: 823,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Antiviral Conjugates (AVCs)",
        companyName: "MYR Pharmaceuticals",
        marketValue: "1570",
        from: "Gilead Sciences",
        to: 824,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Tango Therapeutics",
        marketValue: "2305",
        from: "Gilead Sciences",
        to: 825,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "HiFiBiO Therapeutics",
        marketValue: "NA",
        from: "Gilead Sciences",
        to: 826,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "oNKo-innate",
        marketValue: "NA",
        from: "Gilead Sciences",
        to: 827,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Microbiome-based therapies",
        companyName: "Second Genome",
        marketValue: "338",
        from: "Gilead Sciences",
        to: 828,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Jounce Therapeutics",
        marketValue: "805",
        from: "Gilead Sciences",
        to: 829,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Teneobio",
        marketValue: "NA",
        from: "Gilead Sciences",
        to: 830,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Immunomedics",
        marketValue: "21000",
        from: "Gilead Sciences",
        to: 831,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Non-invasive healthcare devices",
        companyName: "Glympse Bio",
        marketValue: "69",
        from: "Gilead Sciences",
        to: 832,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Forty Seven Inc.",
        marketValue: "4900",
        from: "Gilead Sciences",
        to: 833,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "AlloVir",
        marketValue: "127",
        from: "Gilead Sciences",
        to: 834,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Goldfinch Bio",
        marketValue: "2059",
        from: "Gilead Sciences",
        to: 835,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antiretroviral therapy",
        companyName: "Lyndra Therapeutics",
        marketValue: "122",
        from: "Gilead Sciences",
        to: 836,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Yuhan Corporation",
        marketValue: "785",
        from: "Gilead Sciences",
        to: 837,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Galapagos",
        marketValue: "5050",
        from: "Gilead Sciences",
        to: 838,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Agenus",
        marketValue: "1850",
        from: "Gilead Sciences",
        to: 839,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (ARCUS technology)",
        companyName: "Precision BioSciences Inc.",
        marketValue: "445",
        from: "Gilead Sciences",
        to: 840,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Scholar Rock",
        marketValue: "1530",
        from: "Gilead Sciences",
        to: 841,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Gadeta",
        marketValue: "NA",
        from: "Gilead Sciences",
        to: 842,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antiviral Conjugates (AVCs)",
        companyName: "HOOKIPA Pharma ",
        marketValue: "410",
        from: "Gilead Sciences",
        to: 843,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Verily ",
        marketValue: "NA",
        from: "Gilead Sciences",
        to: 844,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Sangamo Therapeutics",
        marketValue: "3160",
        from: "Gilead Sciences",
        to: 845,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Trianni",
        marketValue: "NA",
        from: "Gilead Sciences",
        to: 846,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Bispecific antibodies",
        companyName: "MacroGenics",
        marketValue: "1760",
        from: "Gilead Sciences",
        to: 847,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein Degradation Therapy",
        companyName: "Nurix Therapeutics",
        marketValue: "2345",
        from: "Gilead Sciences",
        to: 848,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "insitro",
        marketValue: "1050",
        from: "Gilead Sciences",
        to: 849,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Tizona Therapeutics",
        marketValue: "300",
        from: "Gilead Sciences",
        to: 850,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Multiple modalities",
        companyName: "Nimbus Lakshmi, Inc.",
        marketValue: "5000",
        from: "Takeda",
        to: 851,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "Adaptate Biotherapeutics",
        marketValue: "NA",
        from: "Takeda",
        to: 852,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "GammaDelta Therapeutics Limited",
        marketValue: "NA",
        from: "Takeda",
        to: 853,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "Maverick Therapeutics, Inc.",
        marketValue: "525",
        from: "Takeda",
        to: 854,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Nihon Pharmaceutical Co., Ltd",
        marketValue: "52",
        from: "Takeda",
        to: 855,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "PvP Biologics, Inc",
        marketValue: "330",
        from: "Takeda",
        to: 856,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Multiple modalities",
        companyName: "Shire plc ",
        marketValue: "58350",
        from: "Takeda",
        to: 857,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "TiGenix NV",
        marketValue: "608",
        from: "Takeda",
        to: 858,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Larkspur Biosciences",
        marketValue: "35.5",
        from: "Takeda",
        to: 859,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Genomics analysis",
        companyName: "hCBioscience",
        marketValue: "24",
        from: "Takeda",
        to: 860,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Zelluna Immunotherapy",
        marketValue: "NA",
        from: "Takeda",
        to: 861,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "Harness Therapeutics ",
        marketValue: "22.3",
        from: "Takeda",
        to: 862,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "OncoResponse",
        marketValue: "14",
        from: "Takeda",
        to: 863,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Cerevance Inc.",
        marketValue: "51",
        from: "Takeda",
        to: 864,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Non-invasive healthcare devices",
        companyName: "Enzyre",
        marketValue: "13",
        from: "Takeda",
        to: 865,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Genomics analysis",
        companyName: "Integra Therapeutics",
        marketValue: "4.88",
        from: "Takeda",
        to: 866,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Egle Therapeutics SAS",
        marketValue: "46.4",
        from: "Takeda",
        to: 867,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Vaccines",
        companyName: "Frazier Healthcare",
        marketValue: "NA",
        from: "Takeda",
        to: 868,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Partnership",
        modality: "Vaccines",
        companyName: "Biological E. Limited ",
        marketValue: "NA",
        from: "Takeda",
        to: 869,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Protagonist Therapeutics, Inc.",
        marketValue: "300",
        from: "Takeda",
        to: 870,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Small molecule Therapy",
        companyName: "Zedira GmbH",
        marketValue: "NA",
        from: "Takeda",
        to: 871,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "JCR Pharmaceuticals Co., Ltd",
        marketValue: "NA",
        from: "Takeda",
        to: 872,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Arrowhead Pharmaceuticals Inc.",
        marketValue: "1040",
        from: "Takeda",
        to: 873,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Vaccines",
        companyName: "Novavax, Inc. ",
        marketValue: "NA",
        from: "Takeda",
        to: 874,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "MD Anderson",
        marketValue: "NA",
        from: "Takeda",
        to: 875,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "Fujifilm",
        marketValue: "NA",
        from: "Takeda",
        to: 876,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Denali Therapeutics ",
        marketValue: "240",
        from: "Takeda",
        to: 877,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "HUTCHMED (China) Limited",
        marketValue: "1130",
        from: "Takeda",
        to: 878,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Oshi Health",
        marketValue: "23",
        from: "Takeda",
        to: 879,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Belief BioMed Inc. ",
        marketValue: "NA",
        from: "Takeda",
        to: 880,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Amwell ",
        marketValue: "194",
        from: "Takeda",
        to: 881,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "aptihealth ",
        marketValue: "50",
        from: "Takeda",
        to: 882,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "ISHI Health",
        marketValue: "4",
        from: "Takeda",
        to: 883,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Maia Oncology",
        marketValue: "4.25",
        from: "Takeda",
        to: 884,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Rheumission",
        marketValue: "NA",
        from: "Takeda",
        to: 885,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Tele911 Inc",
        marketValue: "NA",
        from: "Takeda",
        to: 886,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: " F-star Therapeutics",
        marketValue: "1000",
        from: "Takeda",
        to: 887,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Arzeda",
        marketValue: "NA",
        from: "Takeda",
        to: 888,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "KSQ Therapeutics",
        marketValue: "510",
        from: "Takeda",
        to: 889,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Atinary Technologies",
        marketValue: "NA",
        from: "Takeda",
        to: 890,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "Artisan Bio ",
        marketValue: "NA",
        from: "Takeda",
        to: 891,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Minimal residual disease (MRD) testing",
        companyName: "Adaptive Biotechnologies Corporation",
        marketValue: "NA",
        from: "Takeda",
        to: 892,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Evozyne, Inc.",
        marketValue: "400",
        from: "Takeda",
        to: 893,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Engitix Ltd",
        marketValue: "300",
        from: "Takeda",
        to: 894,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Anima Biotech",
        marketValue: "NA",
        from: "Takeda",
        to: 895,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "HemoShear Therapeutics, LLC",
        marketValue: "NA",
        from: "Takeda",
        to: 896,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Poseida Therapeutics Inc.",
        marketValue: "6470",
        from: "Takeda",
        to: 897,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "BridGene Biosciences, Inc",
        marketValue: "500",
        from: "Takeda",
        to: 898,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Genevant Sciences",
        marketValue: "600",
        from: "Takeda",
        to: 899,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Codexis, Inc.",
        marketValue: "NA",
        from: "Takeda",
        to: 900,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: " ImmunoGen Inc.",
        marketValue: "34",
        from: "Takeda",
        to: 901,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Elektrofi",
        marketValue: "NA",
        from: "Takeda",
        to: 902,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Peptidream Inc.",
        marketValue: "3500",
        from: "Takeda",
        to: 903,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Code Biotherapeutics",
        marketValue: "2000",
        from: "Takeda",
        to: 904,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Oligonucleotide Therapeutics",
        companyName: "Acurastem",
        marketValue: "580",
        from: "Takeda",
        to: 905,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Selecta Biosciences, Inc.",
        marketValue: "1124",
        from: "Takeda",
        to: 906,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Immusoft",
        marketValue: "900",
        from: "Takeda",
        to: 907,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Ovid Therapeutics",
        marketValue: "856",
        from: "Takeda",
        to: 908,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Implantable medical device",
        companyName: "Nalu Medical",
        marketValue: "65",
        from: "Novo Nordisk",
        to: 909,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Alentis Therapeutics",
        marketValue: "105",
        from: "Novo Nordisk",
        to: 910,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Evosep Aps",
        marketValue: "40",
        from: "Novo Nordisk",
        to: 911,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Implantable medical device",
        companyName: "FIRE1",
        marketValue: "25",
        from: "Novo Nordisk",
        to: 912,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Bispecific antibodies",
        companyName: "Hemab Therapeutics",
        marketValue: "135",
        from: "Novo Nordisk",
        to: 913,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Vaccines",
        companyName: "LimmaTech Biologics",
        marketValue: "37",
        from: "Novo Nordisk",
        to: 914,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "MapLight Therapeutics",
        marketValue: "225",
        from: "Novo Nordisk",
        to: 915,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Octave",
        marketValue: "52",
        from: "Novo Nordisk",
        to: 916,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Acquisition",
        modality: "Antimicrobial Resistance (AMR)",
        companyName: "Paratek Pharmaceuticals",
        marketValue: "462",
        from: "Novo Nordisk",
        to: 917,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Multiple modalities",
        companyName: "Sangon Biotech",
        marketValue: "290",
        from: "Novo Nordisk",
        to: 918,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Terremoto Biosciences",
        marketValue: "175",
        from: "Novo Nordisk",
        to: 919,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Catalent Inc.",
        marketValue: "16500",
        from: "Novo Nordisk",
        to: 920,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "RNA Therapeutics",
        companyName: "Dicerna Pharmaceuticals Inc.",
        marketValue: "3300",
        from: "Novo Nordisk",
        to: 921,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "Forma Therapeutics",
        marketValue: "1100",
        from: "Novo Nordisk",
        to: 922,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Ziylo",
        marketValue: "800",
        from: "Novo Nordisk",
        to: 923,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Breye Therapeutics",
        marketValue: "4.34",
        from: "Novo Nordisk",
        to: 924,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Engimmune Therapeutics AG",
        marketValue: "17.6",
        from: "Novo Nordisk",
        to: 925,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "iECURE",
        marketValue: "65",
        from: "Novo Nordisk",
        to: 926,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "KabaFusion",
        marketValue: "NA",
        from: "Novo Nordisk",
        to: 927,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Genomics analysis",
        companyName: "MedGenome",
        marketValue: "50",
        from: "Novo Nordisk",
        to: 928,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Vaccines",
        companyName: "Ritedose",
        marketValue: "NA",
        from: "Novo Nordisk",
        to: 929,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: " Adcendo",
        marketValue: "62",
        from: "Novo Nordisk",
        to: 930,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antimicrobial Resistance (AMR)",
        companyName: "Bactolife A/S",
        marketValue: "32",
        from: "Novo Nordisk",
        to: 931,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Doctor Anywhere",
        marketValue: "65",
        from: "Novo Nordisk",
        to: 932,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Halodoc",
        marketValue: "135",
        from: "Novo Nordisk",
        to: 933,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Emisphere Technologies Inc.",
        marketValue: "1800",
        from: "Novo Nordisk",
        to: 934,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Staten Biotechnology ",
        marketValue: "485",
        from: "Novo Nordisk",
        to: 935,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Corvidia Therapeutics Inc.",
        marketValue: "2100",
        from: "Novo Nordisk",
        to: 936,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Neotope Neuroscience Limited",
        marketValue: "1200",
        from: "Novo Nordisk",
        to: 937,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Bioprinting Technology",
        companyName: "Aspect Biosystems",
        marketValue: "725",
        from: "Novo Nordisk",
        to: 938,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "ElevateBio",
        marketValue: "401",
        from: "Novo Nordisk",
        to: 939,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Non-invasive healthcare devices",
        companyName: "Biocorp",
        marketValue: "167",
        from: "Novo Nordisk",
        to: 940,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Acquisition",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Embark Biotech",
        marketValue: "471",
        from: "Novo Nordisk",
        to: 941,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: " Inversago Pharma ",
        marketValue: "1075",
        from: "Novo Nordisk",
        to: 942,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Omega Therapeutics Inc. ",
        marketValue: "NA",
        from: "Novo Nordisk",
        to: 943,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Small molecule Therapy",
        companyName: "Cellarity Inc. ",
        marketValue: "NA",
        from: "Novo Nordisk",
        to: 944,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Kakao Healthcare",
        marketValue: "NA",
        from: "Novo Nordisk",
        to: 945,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Partnership",
        modality: "RNA Therapeutics",
        companyName: "Eleven Therapeutics",
        marketValue: "NA",
        from: "Novo Nordisk",
        to: 946,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (CRISPR)",
        companyName: "2seventy bio, Inc. ",
        marketValue: "15",
        from: "Novo Nordisk",
        to: 947,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: " Valo Health Inc.",
        marketValue: "2760",
        from: "Novo Nordisk",
        to: 948,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Harvard University",
        marketValue: "NA",
        from: "Novo Nordisk",
        to: 949,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Dewpoint Therapeutics",
        marketValue: "745",
        from: "Novo Nordisk",
        to: 950,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Asterias Biotherapeutics",
        marketValue: "2",
        from: "Novo Nordisk",
        to: 951,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Microsoft",
        marketValue: "NA",
        from: "Novo Nordisk",
        to: 952,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Non-invasive healthcare devices",
        companyName: "Echosens",
        marketValue: "NA",
        from: "Novo Nordisk",
        to: 953,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "Heartseed Inc.",
        marketValue: "NA",
        from: "Novo Nordisk",
        to: 954,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Small molecule Therapy",
        companyName: "UBE Industries Ltd.",
        marketValue: "NA",
        from: "Novo Nordisk",
        to: 955,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Gene therapy",
        companyName: "bluebird bio Inc. ",
        marketValue: "NA",
        from: "Novo Nordisk",
        to: 956,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Noom",
        marketValue: "NA",
        from: "Novo Nordisk",
        to: 957,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Medtronic",
        marketValue: "NA",
        from: "Novo Nordisk",
        to: 958,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Partnership",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "SomaLogic Inc. ",
        marketValue: "NA",
        from: "Novo Nordisk",
        to: 959,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Almirall ",
        marketValue: "NA",
        from: "Novo Nordisk",
        to: 960,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Ventus Therapeutics, Inc.",
        marketValue: "703",
        from: "Novo Nordisk",
        to: 961,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "EraCal Therapeutics",
        marketValue: "255",
        from: "Novo Nordisk",
        to: 962,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Vect-Horus ",
        marketValue: "327",
        from: "Novo Nordisk",
        to: 963,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Protein Degradation Therapy",
        companyName: " Neomorph, Inc. ",
        marketValue: "1460",
        from: "Novo Nordisk",
        to: 964,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "KBP Biosciences PTE., Ltd. ",
        marketValue: "1300",
        from: "Novo Nordisk",
        to: 965,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Multiple modalities",
        companyName: " Horizon Therapeutics PLC",
        marketValue: "27800",
        from: "Amgen",
        to: 966,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "ChemoCentryx, Inc.",
        marketValue: "3700",
        from: "Amgen",
        to: 967,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Teneobio",
        marketValue: "2500",
        from: "Amgen",
        to: 968,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Five Prime Therapeutics",
        marketValue: "1900",
        from: "Amgen",
        to: 969,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "Rodeo Therapeutics",
        marketValue: "721",
        from: "Amgen",
        to: 970,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Genomics analysis",
        companyName: "Oxford Nanopore Technologies",
        marketValue: "66",
        from: "Amgen",
        to: 971,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Generate Biomedicines",
        marketValue: "1900",
        from: "Amgen",
        to: 972,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Kyowa Kirin Co., Ltd",
        marketValue: "1250",
        from: "Amgen",
        to: 973,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "In-silico drug discovery",
        companyName: "Nuevolution",
        marketValue: "167",
        from: "Amgen",
        to: 974,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein Degradation Therapy",
        companyName: "Arrakis Therapeutics ",
        marketValue: "75",
        from: "Amgen",
        to: 975,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Seismic Therapeutic",
        marketValue: "121",
        from: "Amgen",
        to: 976,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Amazon",
        marketValue: "NA",
        from: "Amgen",
        to: 977,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "TScan Therapeutics, Inc.",
        marketValue: "580",
        from: "Amgen",
        to: 978,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "PostEra Inc.",
        marketValue: "NA",
        from: "Amgen",
        to: 979,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Nanotherapeutics",
        companyName: "EVOQ Therapeutics",
        marketValue: "240",
        from: "Amgen",
        to: 980,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "LegoChem Biosciences, Inc.",
        marketValue: "1250",
        from: "Amgen",
        to: 981,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Neumora Therapeutics Inc.",
        marketValue: "100",
        from: "Amgen",
        to: 982,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "BridgeBio Pharma Inc.",
        marketValue: "NA",
        from: "Amgen",
        to: 983,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein Degradation Therapy",
        companyName: " Plexium, Inc.",
        marketValue: "500",
        from: "Amgen",
        to: 984,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Small molecule Therapy",
        companyName: "IDEAYA Biosciences Inc.",
        marketValue: "NA",
        from: "Amgen",
        to: 985,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Multiple modalities",
        companyName: "BeiGene Ltd.",
        marketValue: "2700",
        from: "Amgen",
        to: 986,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "BigHat Biosciences, Inc.",
        marketValue: "NA",
        from: "Amgen",
        to: 987,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Ontada",
        marketValue: "NA",
        from: "Amgen",
        to: 988,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Provention Bio, Inc.",
        marketValue: "170",
        from: "Amgen",
        to: 989,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "SomaLogic Inc. ",
        marketValue: "NA",
        from: "Amgen",
        to: 990,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "ImmunoScape",
        marketValue: "14",
        from: "Amgen",
        to: 991,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "TileDB Inc.",
        marketValue: "NA",
        from: "Amgen",
        to: 992,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Feldan Therapeutics",
        marketValue: "16.5",
        from: "Amgen",
        to: 993,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Curate Biosciences",
        marketValue: "25.5",
        from: "Amgen",
        to: 994,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Non-invasive healthcare devices",
        companyName: " Olive Diagnostics",
        marketValue: "7.3",
        from: "Amgen",
        to: 995,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "AI-powered diagnostics",
        companyName: "Nervio",
        marketValue: "NA",
        from: "Amgen",
        to: 996,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Protein Degradation Therapy",
        companyName: "Casma Therapeutics",
        marketValue: "46",
        from: "Amgen",
        to: 997,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Kernal Biologics Inc.",
        marketValue: "25",
        from: "Amgen",
        to: 998,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Celsius Therapeutics",
        marketValue: "83",
        from: "Amgen",
        to: 999,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Genome Medical ",
        marketValue: "60",
        from: "Amgen",
        to: 1000,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Digital health tool",
        companyName: "Mindset Medical, LLC",
        marketValue: "NA",
        from: "Amgen",
        to: 1001,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Syapse",
        marketValue: "NA",
        from: "Amgen",
        to: 1002,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "NAVAN Technologies, Inc. ",
        marketValue: "NA",
        from: "Amgen",
        to: 1003,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (ARCUS technology)",
        companyName: "Precision BioSciences Inc.",
        marketValue: "110",
        from: "Amgen",
        to: 1004,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Adaptive Biotechnologies Corporation",
        marketValue: "NA",
        from: "Amgen",
        to: 1005,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Entera Bio Ltd.",
        marketValue: "270",
        from: "Amgen",
        to: 1006,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Nkarta Therapeutics",
        marketValue: "114",
        from: "Amgen",
        to: 1007,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "EnClear Therapies",
        marketValue: "10",
        from: "Amgen",
        to: 1008,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Hummingbird Bioscience",
        marketValue: "100",
        from: "Amgen",
        to: 1009,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Synaffix B.V",
        marketValue: "2000",
        from: "Amgen",
        to: 1010,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Point-of-care testing (POCT)",
        companyName: "LumiraDx",
        marketValue: "350",
        from: "Roche",
        to: 1011,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Telavant",
        marketValue: "7250",
        from: "Roche",
        to: 1012,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Multiple modalities",
        companyName: "Carmot Therapeutics",
        marketValue: "3100",
        from: "Roche",
        to: 1013,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Zion Pharma",
        marketValue: "680",
        from: "Roche",
        to: 1014,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Good Therapeutics",
        marketValue: "250",
        from: "Roche",
        to: 1015,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Genomics analysis",
        companyName: "TIB Molbiol",
        marketValue: "NA",
        from: "Roche",
        to: 1016,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Acquisition",
        modality: "Genomics analysis",
        companyName: "GenMark Diagnostics",
        marketValue: "1800",
        from: "Roche",
        to: 1017,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Lead Pharma",
        marketValue: "293",
        from: "Roche",
        to: 1018,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Enterprise Therapeutics",
        marketValue: "97",
        from: "Roche",
        to: 1019,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "Inflazome",
        marketValue: "451",
        from: "Roche",
        to: 1020,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Genomics analysis",
        companyName: "Stratos Genomics",
        marketValue: "NA",
        from: "Roche",
        to: 1021,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Acquisition",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "Promedior",
        marketValue: "1390",
        from: "Roche",
        to: 1022,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Sarepta Therapeutics",
        marketValue: "2850",
        from: "Roche",
        to: 1023,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Gene therapy",
        companyName: "Spark Therapeutics",
        marketValue: "4300",
        from: "Roche",
        to: 1024,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Nimble Therapeutics",
        marketValue: "1120",
        from: "Roche",
        to: 1025,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Tusk Therapeutics",
        marketValue: "759",
        from: "Roche",
        to: 1026,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "MediLink Therapeutics",
        marketValue: "1050",
        from: "Roche",
        to: 1027,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Genomics analysis",
        companyName: "Foundation Medicine",
        marketValue: "2400",
        from: "Roche",
        to: 1028,
        sector: "Biotechnology",
    },
    {
        partnership: "Acquisition",
        modality: "Electronic Medical Record (EMR) system",
        companyName: "Flatiron Health",
        marketValue: "1900",
        from: "Roche",
        to: 1029,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Inception Sciences",
        marketValue: "NA",
        from: "Roche",
        to: 1030,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Protein Degradation Therapy",
        companyName: "Ignyta",
        marketValue: "1700",
        from: "Roche",
        to: 1031,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Peptidream Inc.",
        marketValue: "1040",
        from: "Roche",
        to: 1032,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Adaptive Biotechnologies Corporation",
        marketValue: "2300",
        from: "Roche",
        to: 1033,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "SQZ Biotech",
        marketValue: "1375",
        from: "Roche",
        to: 1034,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Cell therapy",
        companyName: "Lineage Cell Therapeutics, Inc",
        marketValue: "NA",
        from: "Roche",
        to: 1035,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Genomics analysis",
        companyName: "Dyno Therapeutics",
        marketValue: "1800",
        from: "Roche",
        to: 1036,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "SpliceBio",
        marketValue: "216",
        from: "Roche",
        to: 1037,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Remix Therapeutics",
        marketValue: "1042",
        from: "Roche",
        to: 1038,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "PhoreMost",
        marketValue: "NA",
        from: "Roche",
        to: 1039,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Recursion Pharmaceuticals",
        marketValue: "450",
        from: "Roche",
        to: 1040,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Monte Rosa Therapeutics",
        marketValue: "2050",
        from: "Roche",
        to: 1041,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Enable Injections",
        marketValue: "NA",
        from: "Roche",
        to: 1042,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Alcyone Therapeutics Inc",
        marketValue: "NA",
        from: "Roche",
        to: 1043,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Microbiome-based therapies",
        companyName: "Microbiotica",
        marketValue: "534",
        from: "Roche",
        to: 1044,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein and peptide-based Therapeutics",
        companyName: "UCB",
        marketValue: "2120",
        from: "Roche",
        to: 1045,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Alnylam Pharmaceuticals",
        marketValue: "3110",
        from: "Roche",
        to: 1046,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "AI-powered diagnostics",
        companyName: "Idex Medical Analystics",
        marketValue: "NA",
        from: "Roche",
        to: 1047,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Lodo Therapeutics",
        marketValue: "969",
        from: "Roche",
        to: 1048,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "In-silico drug discovery",
        companyName: "Nvidia",
        marketValue: "NA",
        from: "Roche",
        to: 1049,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Neuroscience Therapy",
        companyName: "NeuExcell Therapeutics",
        marketValue: "190",
        from: "Roche",
        to: 1050,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "MOMA Therapeutics",
        marketValue: "2066",
        from: "Roche",
        to: 1051,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Kronos Bio",
        marketValue: "574",
        from: "Roche",
        to: 1052,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Belharra Therapeutics",
        marketValue: "80",
        from: "Roche",
        to: 1053,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "AI-powered diagnostics",
        companyName: "Herophilus",
        marketValue: "NA",
        from: "Roche",
        to: 1054,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Electronic Medical Record (EMR) system",
        companyName: "PicnicHealth",
        marketValue: "NA",
        from: "Roche",
        to: 1055,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Microbiome-based therapies",
        companyName: "Synlogic, Inc",
        marketValue: "2.5",
        from: "Roche",
        to: 1056,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Jnana Therapeutics",
        marketValue: "1040",
        from: "Roche",
        to: 1057,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Nanotherapeutics",
        companyName: "Berkeley Lab",
        marketValue: "NA",
        from: "Roche",
        to: 1058,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "ShapeTX",
        marketValue: "NA",
        from: "Roche",
        to: 1059,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Genomics analysis",
        companyName: "Freenome",
        marketValue: "254",
        from: "Roche",
        to: 1060,
        sector: "Biotechnology",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "NMD Pharma",
        marketValue: "80",
        from: "Roche",
        to: 1061,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Mironid",
        marketValue: "45",
        from: "Roche",
        to: 1062,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cytokine-based therapeutics",
        companyName: "Bonum Therapeutics",
        marketValue: "93",
        from: "Roche",
        to: 1063,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein Degradation Therapy",
        companyName: "GlycoEra",
        marketValue: "49",
        from: "Roche",
        to: 1064,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Jasper Therapeutics",
        marketValue: "14.1",
        from: "Roche",
        to: 1065,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Nanotherapeutics",
        companyName: "Entrada Therapeutics",
        marketValue: "59",
        from: "Roche",
        to: 1066,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Enliven Therapeutics",
        marketValue: "55",
        from: "Roche",
        to: 1067,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Palladio Biosciences",
        marketValue: "20",
        from: "Roche",
        to: 1068,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Black Diamond Therapeutics",
        marketValue: "85",
        from: "Roche",
        to: 1069,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "IDEAYA Biosciences Inc.",
        marketValue: "94",
        from: "Roche",
        to: 1070,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Poseida Therapeutics Inc.",
        marketValue: "6220",
        from: "Roche",
        to: 1071,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Exosome-based therapeutics",
        companyName: "PureTech Health",
        marketValue: "1036",
        from: "Roche",
        to: 1072,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Partnership",
        modality: "Small molecule Therapy",
        companyName: "Atea Pharmaceuticals",
        marketValue: "NA",
        from: "Roche",
        to: 1073,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Genomics analysis",
        companyName: "Illumina",
        marketValue: "NA",
        from: "Roche",
        to: 1074,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "AI-powered diagnostics",
        companyName: "GE Healthcare",
        marketValue: "NA",
        from: "Roche",
        to: 1075,
        sector: "Medical Devices & Equipment",
    },
    {
        partnership: "Partnership",
        modality: "Organ-on-Chip technology",
        companyName: "Emulate, Inc",
        marketValue: "NA",
        from: "Roche",
        to: 1076,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "Jecure Therapeutics Inc",
        marketValue: "NA",
        from: "Roche",
        to: 1077,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Vaccines",
        companyName: "Nykode Therapeutics",
        marketValue: "715",
        from: "Roche",
        to: 1078,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Syapse",
        marketValue: "NA",
        from: "Roche",
        to: 1079,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Blueprint Medicines Corporation",
        marketValue: "1702",
        from: "Roche",
        to: 1080,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Nanotherapeutics",
        companyName: "GenEdit",
        marketValue: "644",
        from: "Roche",
        to: 1081,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Sosei Heptares",
        marketValue: "1026",
        from: "Roche",
        to: 1082,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Repare Therapeutics",
        marketValue: "1325",
        from: "Roche",
        to: 1083,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Avista Therapeutics",
        marketValue: "1007.5",
        from: "Roche",
        to: 1084,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cell therapy",
        companyName: "Hookipa Pharma",
        marketValue: "970",
        from: "Roche",
        to: 1085,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Precision Therapeutics",
        companyName: "Junshi Biosciences",
        marketValue: "NA",
        from: "Eli Lilly & Co",
        to: 1086,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cell therapy",
        companyName: "Sigilon Therapeutics",
        marketValue: "309.6",
        from: "Eli Lilly & Co",
        to: 1087,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Gene therapy",
        companyName: "Akouos, Inc.",
        marketValue: "610",
        from: "Eli Lilly & Co",
        to: 1088,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Gene therapy",
        companyName: "Prevail Therapeutics, Inc.",
        marketValue: "1040",
        from: "Eli Lilly & Co",
        to: 1089,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Jaguar Gene Therapy",
        marketValue: "139",
        from: "Eli Lilly & Co",
        to: 1090,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Nanotherapeutics",
        companyName: "Entos Pharmaceuticals",
        marketValue: "450",
        from: "Eli Lilly & Co",
        to: 1091,
        sector: "Drug delivery technology",
    },
    {
        partnership: "Acquisition",
        modality: "Multiple modalities",
        companyName: "Dermira",
        marketValue: "1100",
        from: "Eli Lilly & Co",
        to: 1092,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Loxo Oncology, Inc.",
        marketValue: "8000",
        from: "Eli Lilly & Co",
        to: 1093,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Mablink Biosciences",
        marketValue: "NA",
        from: "Eli Lilly & Co",
        to: 1094,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Cytokine-based therapeutics",
        companyName: "ARMO Biosciences, Inc.",
        marketValue: "1600",
        from: "Eli Lilly & Co",
        to: 1095,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "AurKa Pharma, Inc.",
        marketValue: "575",
        from: "Eli Lilly & Co",
        to: 1096,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Neuroscience Therapy",
        companyName: "Disarm Therapeutics",
        marketValue: "1360",
        from: "Eli Lilly & Co",
        to: 1097,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Protomer Technologies",
        marketValue: "1000",
        from: "Eli Lilly & Co",
        to: 1098,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "In-silico drug discovery",
        companyName: "Dice Therapeutics, Inc",
        marketValue: "2400",
        from: "Eli Lilly & Co",
        to: 1099,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "Emergence Therapeutics",
        marketValue: "406.5",
        from: "Eli Lilly & Co",
        to: 1100,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Precision Therapeutics",
        companyName: "Versanis Bio",
        marketValue: "1925",
        from: "Eli Lilly & Co",
        to: 1101,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Radiopharmaceutical therapy",
        companyName: "Point Biopharma Global, Inc.",
        marketValue: "1400",
        from: "Eli Lilly & Co",
        to: 1102,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Small molecule Therapy",
        companyName: "Petra Pharma",
        marketValue: "NA",
        from: "Eli Lilly & Co",
        to: 1103,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Acquisition",
        modality: "Neuroscience Therapy",
        companyName: "Hydra Biosciences",
        marketValue: "NA",
        from: "Eli Lilly & Co",
        to: 1104,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "PRISM BioLab",
        marketValue: "660",
        from: "Eli Lilly & Co",
        to: 1105,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Yseop",
        marketValue: "NA",
        from: "Eli Lilly & Co",
        to: 1106,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "OrsoBio, Inc.",
        marketValue: "60",
        from: "Eli Lilly & Co",
        to: 1107,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Auron Therapeutics",
        marketValue: "48",
        from: "Eli Lilly & Co",
        to: 1108,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (RNAi)",
        companyName: "Laverock Therapeutics",
        marketValue: "17.1",
        from: "Eli Lilly & Co",
        to: 1109,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Mariana Oncology (Formerly Curie Therapeutics)",
        marketValue: "175",
        from: "Eli Lilly & Co",
        to: 1110,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (RNAi)",
        companyName: "Amber Biosciences",
        marketValue: "26",
        from: "Eli Lilly & Co",
        to: 1111,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "ViaNautis Bio",
        marketValue: "25",
        from: "Eli Lilly & Co",
        to: 1112,
        sector: "Drug delivery technology",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (RNAi)",
        companyName: "Volastra Therapeutics, Inc.",
        marketValue: "60",
        from: "Eli Lilly & Co",
        to: 1113,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "IgGenix, Inc",
        marketValue: "40",
        from: "Eli Lilly & Co",
        to: 1114,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (RNAi)",
        companyName: "Strand Therapeutics",
        marketValue: "45",
        from: "Eli Lilly & Co",
        to: 1115,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Genomics analysis",
        companyName: "Delfi Diagnostics",
        marketValue: "225",
        from: "Eli Lilly & Co",
        to: 1116,
        sector: "Disease Diagnostics and Devices",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (RNAi)",
        companyName: "Artax Biopharma",
        marketValue: "26",
        from: "Eli Lilly & Co",
        to: 1117,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Genomics analysis",
        companyName: "Verge Genomics",
        marketValue: "719",
        from: "Eli Lilly & Co",
        to: 1118,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (RNAi)",
        companyName: "Foghorn Therapeutics Inc.",
        marketValue: "1680",
        from: "Eli Lilly & Co",
        to: 1119,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Regor Therapeutics Group",
        marketValue: "1550",
        from: "Eli Lilly & Co",
        to: 1120,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (RNAi)",
        companyName: "IpiNovyx Bio",
        marketValue: "10",
        from: "Eli Lilly & Co",
        to: 1121,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Nanotherapeutics",
        companyName: "GenEdit",
        marketValue: "26",
        from: "Eli Lilly & Co",
        to: 1122,
        sector: "Drug Delivery Technology",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (RNAi)",
        companyName: "Vanqua Bio",
        marketValue: "85",
        from: "Eli Lilly & Co",
        to: 1123,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein Degradation Therapy",
        companyName: "Lycia Therapeutics, Inc.",
        marketValue: "1635",
        from: "Eli Lilly & Co",
        to: 1124,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (RNAi)",
        companyName: "MiNA Therapeutics Limited",
        marketValue: "1250",
        from: "Eli Lilly & Co",
        to: 1125,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "DTx Pharma",
        marketValue: "100",
        from: "Eli Lilly & Co",
        to: 1126,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (RNAi)",
        companyName: "Evox Therapeutics",
        marketValue: "1220",
        from: "Eli Lilly & Co",
        to: 1127,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Centrexion Therapeutics",
        marketValue: "997.5",
        from: "Eli Lilly & Co",
        to: 1128,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (RNAi)",
        companyName: "Merus N.V.",
        marketValue: "1680",
        from: "Eli Lilly & Co",
        to: 1129,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene editing technologies (ARCUS technology)",
        companyName: "Precision BioSciences Inc.",
        marketValue: "555",
        from: "Eli Lilly & Co",
        to: 1130,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Terns Pharmaceuticals, Inc.",
        marketValue: "87",
        from: "Eli Lilly & Co",
        to: 1131,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Protein Degradation Therapy",
        companyName: "Seed Therapeutics",
        marketValue: "800",
        from: "Eli Lilly & Co",
        to: 1132,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Nido Biosciences",
        marketValue: "109",
        from: "Eli Lilly & Co",
        to: 1133,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Sitryx Therapeutics",
        marketValue: "1160",
        from: "Eli Lilly & Co",
        to: 1134,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Avidity Biosciences",
        marketValue: "null",
        from: "Eli Lilly & Co",
        to: 1135,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "NextCure, Inc. ",
        marketValue: "40",
        from: "Eli Lilly & Co",
        to: 1136,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Therapeutics",
        companyName: "Dicerna Pharmaceuticals Inc.",
        marketValue: "550",
        from: "Eli Lilly & Co",
        to: 1137,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Cytokine-based therapeutics",
        companyName: "Aduro Biotech",
        marketValue: "632",
        from: "Eli Lilly & Co",
        to: 1138,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "RNA Editing Technology",
        companyName: "ProQR Therapeutics N.V. ",
        marketValue: "125",
        from: "Eli Lilly & Co",
        to: 1139,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Isomorphic Labs",
        marketValue: "1745",
        from: "Eli Lilly & Co",
        to: 1140,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "Elektrofi",
        marketValue: "470",
        from: "Eli Lilly & Co",
        to: 1141,
        sector: "Drug delivery technology",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Nimbus Therapeutics",
        marketValue: "496",
        from: "Eli Lilly & Co",
        to: 1142,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Schrödinger, Inc.",
        marketValue: "425",
        from: "Eli Lilly & Co",
        to: 1143,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "Beam Therapeutics",
        marketValue: "600",
        from: "Eli Lilly & Co",
        to: 1144,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "XtalPi Inc.",
        marketValue: "250",
        from: "Eli Lilly & Co",
        to: 1145,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "AC Immune SA",
        marketValue: "2088.81",
        from: "Eli Lilly & Co",
        to: 1146,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Multiple modalities",
        companyName: "Blacksmith Medicines",
        marketValue: "300",
        from: "Eli Lilly & Co",
        to: 1147,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Fauna Bio",
        marketValue: "494",
        from: "Eli Lilly & Co",
        to: 1148,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Gene therapy",
        companyName: "TRexBio, Inc.",
        marketValue: "1155",
        from: "Eli Lilly & Co",
        to: 1149,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "PeptiDream Inc.",
        marketValue: "1235",
        from: "Eli Lilly & Co",
        to: 1150,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Abbisko Therapeutics",
        marketValue: "258",
        from: "Eli Lilly & Co",
        to: 1151,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Sosei Heptares",
        marketValue: "731",
        from: "Eli Lilly & Co",
        to: 1152,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Small molecule Therapy",
        companyName: "Veru, Inc",
        marketValue: "NA",
        from: "Eli Lilly & Co",
        to: 1153,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Partnership",
        modality: "Digital health tool",
        companyName: "Sidekick Health",
        marketValue: "NA",
        from: "Eli Lilly & Co",
        to: 1154,
        sector: "Healthcare SaaS",
    },
    {
        partnership: "Partnership",
        modality: "3D printing technology",
        companyName: "Triastek Inc.",
        marketValue: "NA",
        from: "Eli Lilly & Co",
        to: 1155,
        sector: "Drug delivery technology",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Confo Therapeutics",
        marketValue: "630",
        from: "Eli Lilly & Co",
        to: 1156,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Antibody-Drug Conjugate (ADC)",
        companyName: "ImmunoGen Inc.",
        marketValue: "1713",
        from: "Eli Lilly & Co",
        to: 1157,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Genesis Therapeutics",
        marketValue: "670",
        from: "Eli Lilly & Co",
        to: 1158,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Kumquat Biosciences",
        marketValue: "2070",
        from: "Eli Lilly & Co",
        to: 1159,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Small molecule Therapy",
        companyName: "Rigel Pharmaceuticals",
        marketValue: "960",
        from: "Eli Lilly & Co",
        to: 1160,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "In-silico drug discovery",
        companyName: "Evotec A.G.",
        marketValue: "1000",
        from: "Eli Lilly & Co",
        to: 1161,
        sector: "Drug discovery and Development",
    },
    {
        partnership: "Investment",
        modality: "Precision Therapeutics",
        companyName: "ImmuNext",
        marketValue: "605",
        from: "Eli Lilly & Co",
        to: 1162,
        sector: "Drug discovery and Development",
    },
];

export const modality = [
    {
        "name": "Cell therapy",
        "id": 1
    },
    {
        "name": "Vaccines",
        "id": 2
    },
    {
        "name": "Small molecule Therapy",
        "id": 3
    },
    {
        "name": "In-silico drug discovery",
        "id": 4
    },
    {
        "name": "Gene editing technology (TALEN based)",
        "id": 5
    },
    {
        "name": "Minimal residual disease (MRD) testing",
        "id": 6
    },
    {
        "name": "AI-powered diagnostics",
        "id": 7
    },
    {
        "name": "Digital health tool",
        "id": 8
    },
    {
        "name": "Antibody-Drug Conjugate (ADC)",
        "id": 9
    },
    {
        "name": " Implantable medical device",
        "id": 10
    },
    {
        "name": "Protein Degradation Therapy",
        "id": 11
    },
    {
        "name": "Gene editing technology (Pin-point based)",
        "id": 12
    },
    {
        "name": "Precision Therapeutics",
        "id": 13
    },
    {
        "name": "Neuroscience Therapy",
        "id": 14
    },
    {
        "name": "Gene therapy",
        "id": 15
    },
    {
        "name": "RNA Therapeutics",
        "id": 16
    },
    {
        "name": "Gene editing technologies (CRISPR)",
        "id": 17
    },
    {
        "name": "AI in clinical trials",
        "id": 18
    },
    {
        "name": "Bispecific antibodies",
        "id": 19
    },
    {
        "name": "Ready-To-Use (RTU) infusion oncology products",
        "id": 20
    }
]

export const companyName = [
    {
        "name": "Gracell Biotechnologies",
        "id": 1
    },
    {
        "name": "Omniose",
        "id": 2
    },
    {
        "name": "Icosavax, Inc.",
        "id": 3
    },
    {
        "name": "CinCor Pharma, Inc",
        "id": 4
    },
    {
        "name": "Absci",
        "id": 5
    },
    {
        "name": "Neogene Therapeutics",
        "id": 6
    },
    {
        "name": "Cellectis",
        "id": 7
    },
    {
        "name": "C2i Genomics",
        "id": 8
    },
    {
        "name": "Ibex Medical Analytics ",
        "id": 9
    },
    {
        "name": "Hospital Bellvitge",
        "id": 10
    },
    {
        "name": "Verge Genomics",
        "id": 11
    },
    {
        "name": "QuellTX",
        "id": 12
    },
    {
        "name": "LaNova Medicines",
        "id": 13
    },
    {
        "name": "Ascentage Pharma",
        "id": 14
    },
    {
        "name": "Sernova Corp",
        "id": 15
    },
    {
        "name": "Personalis, Inc.",
        "id": 16
    },
    {
        "name": "Cullgen Inc",
        "id": 17
    },
    {
        "name": "Revvity",
        "id": 18
    },
    {
        "name": "Eccogene ",
        "id": 19
    },
    {
        "name": "Cholesgen ",
        "id": 20
    },
    {
        "name": "Qure.ai",
        "id": 21
    },
    {
        "name": "JCR Pharmaceuticals Co., Ltd.",
        "id": 22
    },
    {
        "name": "Biora Therapeutics, Inc",
        "id": 23
    },
    {
        "name": "AbelZeta Pharma",
        "id": 24
    },
    {
        "name": "TeneoTwo, Inc.",
        "id": 25
    },
    {
        "name": "Neurimmune",
        "id": 26
    },
    {
        "name": "Illumina Inc",
        "id": 27
    },
    {
        "name": "RQ Biotechnology Ltd ",
        "id": 28
    },
    {
        "name": "LogicBio Therapeutics, Inc.",
        "id": 29
    },
    {
        "name": "docdok.health",
        "id": 30
    },
    {
        "name": "Rgenta Therapeutics Inc",
        "id": 31
    },
    {
        "name": "Huma ",
        "id": 32
    },
    {
        "name": "Target Medicals LLC",
        "id": 33
    },
    {
        "name": "Caelum Biosciences, Inc.",
        "id": 34
    },
    {
        "name": "Alexion Pharmaceuticals, Inc.",
        "id": 35
    },
    {
        "name": "Ionis",
        "id": 36
    },
    {
        "name": "VaxEquity",
        "id": 37
    },
    {
        "name": "Accent Therapeutics",
        "id": 38
    },
    {
        "name": "Silence Therapeutics",
        "id": 39
    },
    {
        "name": "ArcherDX",
        "id": 40
    },
    {
        "name": "Dogma Therapeutics",
        "id": 41
    },
    {
        "name": "Daiichi Sankyo Company, Limited",
        "id": 42
    },
    {
        "name": "BenevolentAI ",
        "id": 43
    },
    {
        "name": "Aptamer Group",
        "id": 44
    },
    {
        "name": "Cancer Research UK",
        "id": 45
    },
    {
        "name": "Innate Pharma SA",
        "id": 46
    },
    {
        "name": "IGI Research",
        "id": 47
    },
    {
        "name": "Pelago Bioscience",
        "id": 48
    },
    {
        "name": "Yiviva ",
        "id": 49
    },
    {
        "name": "Sarah Cannon Research Institute (SCRI)",
        "id": 50
    },
    {
        "name": "Cellular Biomedicine Group Inc.",
        "id": 51
    },
    {
        "name": "Allorion Therapeutics ",
        "id": 52
    },
    {
        "name": "Compugen Ltd",
        "id": 53
    },
    {
        "name": "Presage Biosciences",
        "id": 54
    },
    {
        "name": "IMBdx Inc.",
        "id": 55
    },
    {
        "name": "Nanoform Finland",
        "id": 56
    },
    {
        "name": "KYM Biosciences",
        "id": 57
    },
    {
        "name": "Sun Pharmaceutical Industries Ltd.",
        "id": 58
    },
    {
        "name": "ProBioGen",
        "id": 59
    },
    {
        "name": "Regio Biosciences ",
        "id": 60
    }
]

export const sector = [
    {
        "name": "Drug discovery and Development",
        "id": 1
    },
    {
        "name": "Biotechnology",
        "id": 2
    },
    {
        "name": "Healthcare SaaS",
        "id": 3
    },
    {
        "name": "Disease Diagnostics and Devices",
        "id": 4
    },
    {
        "name": "Drug Delivery Technology",
        "id": 5
    },
    {
        "name": "Drug manufacturing",
        "id": 6
    }
]

export const partnership = [
    {
        "name": "Acquisition",
        "id": 1
    },
    {
        "name": "Partnership",
        "id": 2
    },
    {
        "name": "Investment",
        "id": 3
    }
]